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ABSTRACT
Aggrecan is an essential component of articular cartilage and subject to 
regulation by tissue-specific and environmental factors. A series of studies were 
performed in order to identify regulatory elements in the human aggrecan gene, so that 
the molecular mechanisms that control its expression in chondrocytes can be further 
understood. A distal 1.7 kb portion of the aggrecan promoter was cloned and 
sequenced and found to contain an Alu repeat and several putative transcription factor 
binding motifs. In order to identify functionally important regions in the distal and 
proximal regions of the aggrecan promoter and 5’untranslated region (5’ UTR), a 
series of deletion constructs were created using luciferase reporter vectors in cell 
transfection assays. The results showed that the 5’UTR had a major effect on basal 
promoter activity, causing a 5- to 7-fold increase in luciferase expression in both 
chondrocytes and NIH 3T3 fibroblasts.
Aggrecan promoter activity in chondrocytes was also found to be modulated by
biochemical and physical stimuli including IL-1, TNFa, osmolality and shear stress.
Results from deletion analysis showed that the 5’UTR is involved in conferring 
responsiveness to these factors, but other sequences in the 2.4 kb promoter are also 
involved. As well as extracellular factors, our studies demonstrated that aggrecan gene 
expression is modulated by a major intracellular signalling pathway. Blocking the 
activity of MEK-1 (MAPKK-1) in normal and transfected chondrocytes was found to 
induce a 4-fold increase in aggrecan mRNA levels and promoter activity. MEK-1 
inhibition also prevented fluid-flow induced down-regulation of aggrecan promoter 
activity. Subsequent deletion analysis identified a 162 bp region in the 5’UTR that 
mediates responsiveness to MEK-1 signalling. The results obtained from this series of 
studies indicates that the 5’UTR contains at least two regions that regulate aggrecan 
gene expression; one region is essential for basal promoter activity, and the other
modulates promoter activity in response to signals that stimulate the MEK-1/MAPK 
cascade.
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Chapter 1: INTRODUCTION
1.1. The structure and function of articular cartilage
Aggrecan is a major structural component of articular cartilage, the tissue that 
forms the load-bearing surface of articulating bony ends within diarthrodial (freely 
moving) joints. Articular cartilage plays a vital role in the function of the 
musculoskeletal system by allowing almost frictionless motion to occur between these 
articulating surfaces. It also confers unique biomechanical properties on the joint 
including stiffness to compression and resiliency, and the capacity to distribute loads 
(Mow and Ratcliffe, 1991), thereby minimizing exposure of the underlying bone to 
high mechanical stresses. These mechanical properties depend on the structural 
composition and ultrastructural organization of the tissue, particularly the collagens 
and proteoglycans of the extracellular matrix (ECM).
Articular cartilage consists of a dense extracellular matrix (ECM) which 
contains two distinct phases: a solid phase, composed of chondrocytes, collagen 
fibrils, proteoglycans and other glycoproteins; and a fluid phase composed of water 
and electrolytes. At the microscopic level, the stuctural composition and organization 
of the extracellular matrix varies according to the depth of the cartilage from the 
articulating surface. The changes in chondrocyte morphology and matrix organization 
make it possible to identify four layers or zones from the articular surface to the 
subchondral bone, and are referred to as the superficial zone, transitional zone, deep 
zone, and zone of calcification (figure 1-a). In addition to the zonal variations, each 
zone is comprised of pericellular, territorial and interterritorial regions, based on its 
proximity to the chondrocyte. The pericellular and territorial regions are closely 
associated with the chondrocyte and contain a distinct collagen fibril arrangement that 
may provide mechanical protection for the chondrocyte during loading (Buckwalter et 
al., 1990). The interterritorial region makes up most of the volume of mature articular 
cartilage and is thought to contribute to the majority of its material properties.
Chondrocytes are the only cell type found in normal mature articular cartilage 
and occupy less than 10% of the total tissue volume. The chondrocyte phenotype is 
characterized by a spheroidal shape and the expression of cartilage matrix proteins, 
including type II collagen, link protein and aggrecan. The synthesis, incorporation and 
degradation of these proteins is orchestrated by chondrocytes through an appropriate 
balance of anabolic (synthetic) and catabolic (degradative) events. Simultaneous 
synthesis and proteolytic breakdown of ECM components enables the cartilage matrix 
to undergo continual maintenance and repair, and this is necessary for normal cartilage 
function throughout life. Chondrocyte metabolism is in turn regulated by 
environmental factors. These include soluble mediators (e.g cytokines, growth factors 
and some pharmaceutical agents), mechanical loads, hydrostatic pressure, matrix 
composition, and electric fields. These factors are regarded as being necessary for 
normal cartilage homeostasis. Impaired chondrocyte function due to tissue trauma, or 
chronic and progressive joint disease, can upset the balanced equilibrium of synthesis 
and catabolism which may lead to the slow degenerative process of osteoarthritis.
Proteoglycans comprise the second largest portion of organic material in 
articular cartilage (Keettner et al., 1986; Muir, 1983) (table 1) and have been 
extensively studied in this tissue because of their importance in joint function, skeletal 
growth, and development of osteoarthritis. They are a family of highly structured 
proteins found in connective tissues throughout the body and are characterized by the 
presence of one or more glycosaminoglycan (GAG) chains, covalently attached to the 
protein core (Hardingham and Fosang, 1992a; lozzo, 1998). The major proteoglycans 
present in articular cartilage are aggrecan (present in aggregating and non-aggregating 
forms) and the small leucine-rich proteoglycans biglycan, decorin and fibromodulin. 
The small proteoglycans are genetically distinct, low molecular weight proteins that 
contain small numbers of glycosaminglycan chains and are present in large numbers in 
articular cartilage. Although their function in cartilage is unclear, decorin and 
fibromodulin have been implicated in organization of the extracellular matrix by 
controlling collagen fibrillogenesis (lozzo, 1998).
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Figure 1-a. Schematic representation of normal adult articular cartilage.
Articular cartilage is composed of extracellular matrix and chondrocytes. The 
tissue is organized into four major zones from the articular surface the subchondral 
bone which can be identified by changes in the distribution and orientation of 
chondrocytes. These consist of a superficial tangential zone, a middle zone, a deep 
zone, and a zone of calcified cartilage. The extracellular matrix within each zone 
is further organized into pericellular, territorial, and interterratorial regions which 
are identified by collagen and proteoglycan distribution. (Adapted from Mow, V. 
C , Proctor, C. S., and Kelly, M. A. (1989) Biomechanics of Articular Cartilage. 
In: Nordin, M and Frankel, V. H. eds, Basic Biomechanics o f the Musculoskeletal 
System, 2nd Ed. Pp 31-58, Lea and Febiger, London)
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Component % wet weight
Water (containing 
dissolved electrolytes: 
Na+, K+, Cl , SO /')
65 to 80 Quantitatively major components
Collagen (type II) 10 to 20
Aggrecan 4 to 7
Other proteoglycans 
-biglycan 
-decorin 
-fibromodulin
Quantitatively minor components 
(less than 5%)
Collagens
-types V, VI, IX, X, 
and XI
Link protein
Hyaluronan
Fibronectin
Lipids
Table 1: The biochemical composition of articular cartilage. Articular 
cartilage consists of a fluid phase containing water and electrolytes and a solid phase. 
The solid phase principally contains two major classes of macromolecules, collagens 
and proteoglycans. The quantitatively minor components are present in lower overall 
amounts per % of the total wet weight, but may be present in equimolar amounts 
compared to the macromolecules such as type II collagen and aggrecan (for example 
link protein).(Adapted from Mankin, H. J., Mow, V. C., Buckwalter, J. A., lonotti, 
J. P and Ratcliffe, A. (1994) Form and Function of Articular Cartilage. In: Simon, S . 
R. ed, Orthopaedic Basic Science, pp 1-44, American Academy of Orthopaedic 
Surgeons, Rosemont, Illinois.
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Aggrecan is the large aggregating proteoglycan of articular cartilage, and is 
present in aggregating and non-aggregating forms (monomers) (Rosenberg et al., 
1975; Hascall, 1977). Aggregates are formed from the non-covalent association of of 
aggrecan monomers with a hyaluronan monofilament, and link proteins (Hardingham 
and Muir, 1972, 1974; Hascall and Heinegard, 1974) which help stabilize the 
monomers on the hyaluronan chain (Hardingham, 1979; Buckwalter et al., 1984). The 
aggregates are restrained in an organized collagen network (containing type II collagen 
with smaller amounts of type I, V, VI, IX and XI) which provides further structural 
rigidity to the extracellular matrix (fig. 1-b).
Each aggrecan monomer contains over a hundred highly sulphated, negatively 
charged glycosaminoglycan (GAG) chains covalently attached to its protein core (fig. 
1-c), creating a highly polyanionic environment. The functional properties of aggrecan 
reside in its ability to form macromolecular aggregates with hyaluronan and 
concentrate negative charges (fig 1-c). The charge to charge repulsion between the 
GAG chains creates a Donnan osmotic pressure that draws water into the tissue and 
extends the collagen network to a stretched state (Mow et al., 1992). This generates a 
hydrated tissue with a high tensile stiffness that can withstand significant mechanical 
loads. As well as regulating tissue hydration, aggrecan largely contributes to the 
compressive stiffness, and viscoelastic properties of cartilage in tension and shear 
(Mow et al., 1992). These unique biomechanical properties depend on the ability of 
aggrecan to form macromolecular aggregates with hyaluronan, that become 
immobilized in the collagen network. Therefore correct synthesis and processing of 
aggrecan by chondrocytes is vital for its function in articular cartilage.
Aggrecan is also essential to the function of cartilage during skeletal 
development. During long bone development, cartilage provides the template for bone 
deposition by osteoblasts and this is necessary for the directed linear growth in the 
growth plates of long bones. In addition to cartilage, aggrecan is expressed in the 
invertebral disc (In@rot and Axelsson, 1991a) meniscus and tendon (Vogel et al., 
1994, 1996) where it is also likely to have a biomechanical function. Aggrecan has
5
also been identified at distinct embryonic stages (before chondrogenesis) in the ECM 
of the developing brain and notochord (Schwartz et ah, 1996). Its role has not been 
clearly defined, but it has been implicated in inhibiting the migration of neurons and 
neural crest cells. The central importance of aggrecan in cartilage has led to extensive 
characterization of its structure in both normal and diseased tissue.
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Aggrecan
Hyaluronan
Interstitial fluid
Collagen fibril
Attached aggrecan
40 nm.
Figure 1-b. Molecular organization of the articular cartilage extracellular 
matrix. Proteoglycan aggregates consisting of aggrecan monomers, hyaluronic 
acid (hyaluronan) and link protein interact with the collagen network and become 
immobilized. The immobilization of aggrecan molecules creates a high fixed 
negative charge due to the glycosaminoglycan side chains which attract positive 
counter ions and in turn water is drawn into the tissue to maintain osmotic balance. 
The influx of water inflates the collagen network creating a highly hydrated and 
resilient tissue that can withstand high mechanical loads. (Adapted from Mow, V. 
C., Proctor, C. S., and Kelly, M. A. (1989) Biomechanics of Articular Cartilage. 
In: Nordin, M and Frankel, V. H., eds, Basic Biomechanics o f the Musculoskeletal 
System, 2nd Ed. Pp 31-58, Lea and Febiger, London)
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Figure 1-c. A A schematic diagram of aggrecan binding to hyaluronan.
Aggrecan monomers bind to a long filamentous proteoglycan, hyaluronan, via 
characteristic repeat sequences in the G l globular domain at the amino-terminus 
end of the protein core. The interaction is stabilized by link protein which binds to 
hyaluronan via the same repeat sequences in its G l domain. B Aggrecan 
monomers forming a proteoglycan aggregate. Hundreds of aggrecan molecules 
can bind to a single hyaluronan chain creating a macromolecular aggregate that 
becomes immobilised in the collagenous network.
1.2. The protein structure of aggrecan
The aggrecan core protein is a highly organized structure, composed of three 
globular domains G l, G2 and G3, and a large extended glycosaminoglycan attachment 
region. The primary structure and complete coding sequence of aggrecan has been 
determined fom cDNA cloning and sequencing studies on a number of species 
including human (Doege et al., 1991) rat (Doege et al., 1987) chicken 
(Chandrasekaran and Tanzer, 1992) and mouse (Walcz et al., 1994; Watanabe et al.,
1995) and partial sequences have been obtained for bovine aggrecan (Antonsson et al., 
1989). The amino acid sequences are well conserved for most regions of aggrecan 
between different species, and the highest degree of homology is found in the globular 
domains G l, G2 and G3 (Doege et al., 1991; Chandrasekaran and Tanzer, 1992).
The Gl globular domain is found at the amino-terminus end of aggrecan, and 
has the specific function of binding with hyaluronan in the extracellular matrix 
(Weidemann et al., 1984). This interaction is stabilized non-covalently by a separate 
link protein in a 1:1 molar ratio with aggrecan (figure 1-c A). The Gl domain is 
characterized by three disulphide-bonded loop structures A, B, and B \ The N-terminal 
A loop shares sequence homology with the immunoglobulin superfamily (Bonnet et 
al., 1986) and is thought to mediate the interaction with link protein via its 
homologous A loop. The B and B’ loops of the Gl domain are homologous loops also 
known as proteoglycan tandem repeats! The tandem repeats are likely to mediate 
binding with hyaluronan, as the similar B and B’ motifs in link protein have been 
shown to contain hyaluronan binding sites (Goetink et al., 1987). As well as aggrecan 
and link protein the tandem repeat motifs are also present in other hyaluronan binding 
proteins including CD44, versican, brevican and neurocans (Hardingham and Fosang, 
1992a; lozzo, 1998). The Gl domain is separated from G2 by a rod-shaped 
interglobular domain (IGD). The IGD contains sites for proteolytic cleavage by 
degradative enzymes known to be involved in aggrecan breakdown (Roughley and 
Lee, 1994) and may therefore be an important feature in aggrecan turnover in the ECM
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and cartilage degeneration. The G2 domain also contains homologous B and B’ loops, 
but does not contain an A loop. Despite the homology with G l, G2 does not have the 
capacity to bind hyaluronan (Fosang and Hardingham, 1989) and its function is 
unknown.
Adjacent to the G2 domain is the glycoasaminoglycan (GAG) attachment 
region which contains chondroitin sulphate (CS), keratan sulphate (KS), and 8-10 
shorter oligosaccharides. Glycosaminoglycans are long, linear carbohydrate chains 
that consist of repeating, glucose-derived dissaccharide units that contribute to 90% of 
the mass of the protein. GAG chains are defined by the glucose moiety that comprises 
the dissaccharide unit and there are a typical number of units per chain (table 2). For 
example, the CS chains of aggrecan are composed of 40-50 repeats of glucoronic acid 
- N-acetyl glucosamine (GluUA - GalNAc), and the KS chains contain 20-25 repeats 
of galactose - N-acetyl glucosamine (Gal - GalNAc). The carbohydrate residues are 
also extensively sulphated and carry carboxyl groups, generating a high concentration 
of negative charges on each aggrecan molecule.
An average aggrecan monomer contains 30 keratan sulphate chains and over 
100 chondroitin sulphate chains, but these numbers vary between species. The 
variability in GAG number is primarily due to the presence and absence of amino acid 
motifs in the aggrecan protein sequence that serve as attachment sites for GAG chains. 
The KS domain in human and bovine aggrecan contains a glutamic acid-proline rich 
hexapeptide repeat sequence that specifies KS attachment (Doege et al., 1991; 
Antoÿnsson et al., 1989). However, this repeat is poorly conserved in the chick and 
rat (Upholt et al., 1993) and suggests that other sequences are involved in binding KS 
in these animals. Similarly, a larger CS domain contains a series of serine-glycine 
tandem repeats that specify chondrotin sulphate substitution. The size of the domain 
varies between species and the region is divided into CS subdomains based on the 
organization and conservation of Ser-Gly sequence repeats (Doege et al., 1991; Upholt 
et al., 1993).
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The third globular domain (G3) is found at the c-terminus of aggrecan. It 
contains subdomains that show primary sequence homology to structural motifs 
characteristic of the selectin family (Springer and Laskey, 1991). The subdomains 
found within the G3 region of aggrecan share homology with epidermal growth factor 
(EGF1 and EGF2), lectin (LEG) and complement regulatory protein (CRP). Their 
individual fuctions are unknown, but the selectin homologies suggest a role in 
carbohydrate and protein recognition. In addition, the EGF1 (Baldwin et al., 1989). 
EGF2 (Fulop et al., 1993) and CRP (Doege et al., 1991; Baldwin et al., 1989) 
domains are alternatively spliced, and show species specific expression, but the 
physiological significance of this has not been determined. The G3 domain is not 
considered to have a major role in matrix assembly as it is present in only a proportion 
of aggrecan molecules in mature cartilage (Dennis et al., 1990). It has been proposed 
that the function of the G3 domain is to mediate intracellular trafficking of aggrecan. 
This hypothesis is based on studies of the nanomelic chick, in which a truncated 
aggrecan molecule lacking the G3 domain is produced (Li et al., 1993). In the absence 
of the G3 domain, the truncated aggrecan precusor accumulates in the endoplasmic 
reticulum and is not secreted from the cell (Vertel et al., 1993). Evidence also exists 
that G3 may be neccessary for the correct processing of GAG chains (Luo et al.,
1996).
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Table 2.
A Typical
rayeosanünogiycan a s^ W id e s
(GAG) per chain Structure
Hyaluronan (HA)
Chondroitin 
Sulphate (CS)
Keratan 
Sulphate (KS)
Dermatan 
Sulphate (DS)
Heparan
Sulphate/Heparin
10000 -(j3ÏcA)— ÇlalNAc)— (SïcA)—(blcNAc)-
4S04 6SO4
50 —^ïcA )— (faalNAc)— (Ç3ÏcA)— ^jalNAc)-
6SO4 6SO4 6SO4
20 —(G d ^— (plcNAc)— (GaT)— (GlcNAc)—
2SO/ 4SO/ 6SO4
50 -^ d A )— (GalNAc)— ^ïcA )— (GalNAc)—
2S04
50 -ridÀ :
680/ 680/
Glcv
B
Proteoglycan GAG type GAG number
*(%2(1X) CS/DS 1
*Aggrecan CS/KS >100
*Biglycan CS/DS 2
*Decorin CS/DS 1
*Fibromodulin KS 4
Perlecan HS/CS 3
Versican CS/DS >10
1 2
Table 2. Properties of glycosaminoglycans. A  Basic structure The GAG
chains consist of repeating glucose-derived disaccharide units which are sulphated at 
specific positions. It should be noted that variations of the basic dissaccharide repeat 
sequence also occur due to epimerization and alternate sulphation of glucose structures 
(Hardingham and Fosang, 1992a). GalNAc, N-acetyl galactosamine; GlcA, 
glucoronic acid; GlcNAc, N-acetyl glucosamine; GlcNSOS, glucosamine-N-sulphate; 
IdA, iduronic acid. B  Glycosaminoglycans of common proteoglycans. * 
denotes proteoglycans found in articular cartilage. Perlecan is a epithelial basement 
membrane proteoglycan and versican is a hyaluronan-binding proteoglycan expressed 
by fibroblasts. It should also be noted that the glycosaminoglycan, hyaluronan does 
not form a covalent link with a protein. (Adapted from Roughley, P. J, and Lee, E. R. 
Cartilage proteoglycans: Structure and potential functions. Microscopy Research and 
Technique 28, 385-397, 1994.)
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The chondrocyte has a highly elaborate endoplasmic reticulum (ER) and Golgi,^ 
which are the sites of a series of complex biosynthetic reactions that are necessary for 
the production of a functional aggrecan molecule. The reactions include protein 
translation and folding, addition of N-linked and O-linked oligosaccharides, and GAG 
chain formation. They occur sequentially through the specific compartments of the 
constitutive secretory pathway (figure 1-d). KS and CS GAG chain formation occurs 
through a series of concurrent polymerization and sulphation reactions in the Golgi 
compartments (Silbert and Sugamaran, 1995), but the multienzyme complexes that 
mediate these processes have not been clearly defined. Correct synthesis and 
processing is thought to be aided by quality control mechanisms that ensure movement 
through the secretory pathway (Alonso et al., 1996). Molecular chaperones are also 
involved in coordinating intracellular trafficking, for example, hsp 25 has been 
implicated in folding the G3 domain and allowing exit of the aggrecan core protein 
from the ER (Zheng et al., 1998).
Structural differences have been observed between aggrecans of different 
tissues. For example, KS-everpresent in cartilage aggrecan, is not present in the 
tensional regions of bovine tendon (Vogel et al., 1994) or the developmental chick 
notochord and brain (Schwartz et al., 1996). Other differences have been noted with 
regard to the distribution and size of CS chains, and the presence of a HNK-1 epitope 
(a 3-sulphoglucoronic acid residue) in chick brain aggrecan (Schwartz et ah, 1996). 
Although the functional significance of these differences is not clear, these 
observations indicate that aggrecan post-translational processing is subject to tissue- 
specific and developmental regulation.
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Key:
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o O-linked oligosacccharide # Xylose — CS linkage sugar o— keratan sulphate (KS) © link protein
Figure 1-d. Schematic overview of aggrecan synthesis and processing in 
specific intracellular compartments of the secretory pathway. Major 
modifications include: 1. aggrecan translation and folding, addition of N-linked 
oligosaccharides; 2. addition of xylose for CS chain initiation; 3. addition of CS 
linkage sugars; 4. polymerization and sulphation of CS chains, addition of O- 
linked oligos for KS chain initiation; 5. polymerization and sulphation of KS and 
CS; 6. secretion and assembly of aggrecates of link protein, hyaluronan and 
aggrecan followed by association with collagen network. (Adapted from Vertel, B. 
M. (1995) The ins and outs of aggrecan. Trends in Cell Biology 5,458-464)
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1.3 Cartilage pathology
1.3.1. Genetic diseases of articular cartilage
The importance of aggrecan in the extracellular matrix is emphasized by the 
phenotypic effects of genetic diseases of animals in which aggrecan is either absent or 
altered. Two autosomal recessive chondrodysplasias, nanomelia in chicken (Li et ah,
C*jct
1993), and cartilage matrix deficiency (emd) mouse (Watanabe et al., 1994) are caused 
by genetic mutations in the aggrecan gene. Consequently aggrecan is improperly 
processed and absent from the cartilage ECM. In both cases gross skeletal 
abnormalities develop, including tracheal collapse which causes abortion of the 
embryo. No genetic defects for the human aggrecan gene have been identified.
A genetic mutation of an enzyme involved in aggrecan processing has been 
identified in the brachymorphic (bm) mouse (Lyle et al., 1995). The mutation reduces 
activity of phosphoadenosine phosphosulphate (PAPS), an enzyme used in the 
sulphation of glycosaminoglycan chains. As a result aggrecan is undersulphated and 
the cartilage tissue volume is reduced due to a loss of negative charge in the ECM. The 
mutation is not lethal, but causes cartilage abnormalities and dwarfism in homozygous 
mice. Interestingly, sulphation deficiencies in aggrecan processing have been linked to 
human short-limb chondrodysplasia (Supti-Furga et ah, 1996) and diastrophic 
dysplasia (Hastabacka et al., 1994). These diseases illustrate the importance of correct 
aggrecan processing in order to maintain the function of articular cartilage. In the 
degenerative disease of osteoarthritis more subtle changes in aggrecan structure are 
observed, and joint pathology is characterized by depletion of aggrecan from the 
tissue.
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1.3.2. Characteristic features of articular cartilage degeneration
Osteoarthritis is a progressive disease characterized by the destruction of 
articular cartilage. The exact cause of OA is unknown, but a number of factors such as 
aging, joint destabilization due to injury, and alterations in chondrocyte activity have 
been considered to contribute to the intiation and progression of the disease. During 
the progression of OA there are a number of degenerative changes in the biochemical 
composition and biomechanical properties of articular cartilage. The biochemical 
changes include increased hydration (McDevitt and Muir, 1976; Brocklehurst et al., 
1984; Guilak et al., 1994) a net loss of proteoglycans (Guilak et al., 1994^Venn and 
Maroudas, 1977; Inerot et al., 1991) and variations in collagen content and fibril 
arrangement (Wiltberger and Lust, 1975; Stockwell et al., 1983). As a result of these 
structural changes the load bearing ability of the tissue is compromised. A decrease in 
tensile stiffness of OA articular cartilage has been observed (Kempson et al., 1971; 
Guilak et al., 1994) due to disruption of the collagen network. The compressive 
stiffness also decreases and this has been shown to be associated with tissue 
hydration, proteoglycan content and permeability (Setton et al., 1994). These and 
other structure function relationships support the hypothesis that structural changes 
alter the material properties of OA cartilage. As the disease progresses these changes 
cause the load bearing mechanism to fail, and the underlying bone is exposed to 
abnormal mechanical stresses.
The decrease in proteoglycan content in OA is thought to be linked to the 
severity of the disease. Consequently the properties of proteoglycan macromolecules 
in OA have been well studied. Normal cartilage aggrecan is non-covalently bound to 
long hyaluronic acid filaments via the Gl domain in the presence of link protein, 
forming large molecular aggregates as illustrated in figure 1-c. Studies using 
experimental OA canine models have shown a number of changes in the properties of 
aggrecan compared to normal cartilage, including: 1) an increase in the proportion of 
extractable aggrecan (McDevitt and Muir, 1976) indicating that aggrecan is in the non­
aggregating form; 2) synthesis of aggrecans that do not form aggregates with
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hyaluronan (Ineret et al., 1991; Camey et al., 1985) and 3) increased release of 
proteoglycans from the cartilage matrix (Camey et al., 1984; Ratcliffe et al., 1992). 
These OA associated changes prevent the formation of a stable proteoglycan network. 
The accelerated release of proteoglycan and other matrix components may be due to 
increased activity of matrix proteinases. Increased levels of matrix metalloproteinases 
have been detected in experimental (Pelletier et al., 1988) and human osteoarthritis 
(Martel-Pelletier et al., 1984). These proteases cleave aggrecan at specific sites along 
the protein core, reducing chain length and releasing the GAG-containing portion of 
the aggrecan molecule.
Increased biosynthetic activity has also been reported in articular cartilage 
during the early stages of OA (Sandy et al., 1984). This is considered to be a 
mechanism used by chondrocytes for repair. However, subtle changes in aggrecan 
structure in have been observed in early OA cartilage, including increased chondroitin 
sulphate chain length (Camey et al., 1985) and glycosaminoglycan distribution (Cox et 
al., 1985). These changes suggest that the synthetic processes of chondroc^ps are 
altered during OA, but the significance of these changes is not clear. In contrast, no 
differences have been observed between the catabolic processes that cause 
proteoglycan breakdown in OA and those in normal cartilage. Therefore the factors 
involved in degradation of articular cartilage are likely to be the same for normal and 
osteoarthiitic cartilage. Despite increases in biosynthetic activity, the accelerated 
breakdown of proteoglycans in OA cartilage causes their net loss from the tissue.
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1.4. Factors that regulate aggrecan synthesis in chondrocytes
Environmental factors stimulate chondrocytes to maintain a balanced 
equilibrium of synthesis and catabolism of extracellular matrix proteins including 
aggrecan, as discussed previously. Exposure of chondrocytes to environmental stimuli 
that fall outside of normal physiological ranges may upset this balance and cartilage 
degradation may result. Understanding the role of environmental factors in the control 
of aggrecan metabolism is essential for therapeutic modulation of disease processes 
such as OA. A commonly used method in the measurement of aggrecan synthesis is 
-sulphate incorporation (into GAG side chains present on each aggrecan moleculeX#^ 
This method is not completely specific for aggrecan as 35S-sulphate will also be 
incorporated into other proteoglycans present in cartilage. However, as aggrecan is 
the predominant proteoglycan synthesized this method is considered acceptable.
1.4.1. Regulation by mechanical stimuli
Altering the mechanical environment of chondrocytes has been shown to affect 
their anabolic and catabolic activities and is a controlling factor for normal 
maintenance of articular cartilage. In vivo studies using experimental animal models 
have shown that altering the mechanical loading of joints results in cartilage pathology.
For example, decreased loading occurs in joint disuse, as demonstrated by the canine 
model of disuse atrophy. In this model, cast immobilization generates an altered 
mechanical environment and causes increased proteoglycan degradation ( Poukkonen 
et al., 1984; Behrens et al., 1989; Ratcliffe et al., 1993) suppression of proteoglycan 
synthesis (Behrens et al., 1989) and cartilage atrophy (Palmoski and Brandt, 1981). 
However, re-establishing the mechanical environment by joint remobilization reverses 
the suppression of proteoglycan synthesis and restores the mechanical properties of 
articular cartilage (Setton et al., 1997). These studies demonstrate that normal 
maintenance of articular cartilage requires a minimal level of loading and joint motion.
The experimental model of animal osteoarthritis uses a surgically-induced procedure to
19
promote joint instability by transection of the anterior cruciate ligament (ACL). ACL 
destabilization results in changes in articular cartilage that resemble human 
osteoarthritis, including alterations in mechanical properties (Altman et ah, 1984; 
Guilak et al., 1994) increased proteoglycan degradation (Camey et al., 1992; Ratcliffe 
et al., 1994) and a significant reduction in cartilage thickness over a prolonged period 
(Brandt et al., 1991). However, increased proteoglycan synthesis has also been 
reported (Malemud, 1991) suggesting that impairment of proteoglycan processing and 
aggregate formation are the events that may be ultimately responsible for cartilage 
degeneration.
Loading of articular cartilage generates a complex series of mechanical, 
physicochemical, and electrical effects at the tissue and cellular level (table 3). A range 
of in vitro studies have been performed in order to characterize the regulatory signals 
derived from the mechanical environment of a chondrocyte. These studies are 
frequently performed on cartilage explant culture, because it preserves the environment 
of the chondrocyte and extracellular matrix, and allows analysis of the chondrocyte 
response under controlled biomechanical and biochemical conditions. These studies 
have shown that in general, long-term static compression of cartilage suppresses 
proteoglycan synthesis (Sah et al., 1989; Burton-Wurster et al., 1993; Guilak et al., 
1994) while short-term cyclic compression at specific frequencies and amplitudes can 
stimulate proteoglycan synthesis (Palmoski and Brandt, 1984; Sah et al., 1989; 
Parkkinen et al., 1992). Changes in hydrostatic pressure have been found to induce 
both a stimulation and suppression of proteoglycan synthesis, but as with compression 
the response is dependent on the mode of loading (Hall et al., 1991; Parkkinen et al., 
1993; Smith et al., 1996).
Quantitation of aggrecan mRNA levels by PCR (Re et al., 1995) is a more 
specific method of assessing aggrecan synthesis but it is used less commonly than 35S- 
sulphate incorporation. Aggrecan mRNA levels have been shown to be transiently 
increased in response to static compression (Valhmu et al., 1998c) but do not change 
after loading periods of more than 4hrs. In contrast, the same loading conditions show
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a decrease in proteoglycan synthesis when measured by 35S-Sulphate incorporation 
(Sah et al., 1989; Guilak et al., 1994). The lack of correlation between aggrecan 
mRNA levels and 35S-sulphate incorporation have also been observed in articular 
cartilage in response to cyclic (Lammi et al., 1994) and constant (Smith et al., 1996) 
hydrostatic pressure. These observations reflect the limitations in the methods used to 
measure aggrecan synthesis and may be explained by translational and/or 
posttranslational regulation of aggrecan expression.
Mechanical loading imposes a number of changes on the physical environment 
of a chondrocyte, including changes in the ionic and osmotic composition of the 
interstitial fluid (table 3) and it is likely that the cells will respond to some or all of 
these signals. Studies have been performed to test if these specific physicochemical 
changes can simulate the observed biological responses of a chondrocyte to mechanical 
load. In both cartilage explants and isolated chondrocytes proteoglycan synthesis is 
inhibited by increasing media osmolality (Urban et al., 1993; Borghetti et al., 1994). 
Proteoglycan synthesis is also inhibited by decreasing the media pH (Urban and Hall,
1994) and in epiphyseal cartilage, synthesis rates observed with compression correlate 
well with synthesis rates in decreasing pH (Gray et al., 1988). These results support 
the hypothesis that the effects of mechanical load are at least partly due to the changes 
in the ionic and osmotic environment of a chondrocyte.
2 1
1. Increase in hydrostatic pressure
2. Extracellular matrix and chondrocyte deformation
3. Fluid flow
4. Streaming potentials (generated by the movement of fluid through a charged matrix)
5. Fluid loss
6. Increased glycosaminoglycan (GAG) concentration
7. Changes in ionic composition of the ECM:
a) Increased cation (H+, Na+, K+, Ca2+) concentrations
b) decreased anion (Cl", HC03", S042") concentrations
c) Increased osmolality
Table 3: The physical effects generated by the loading of articular 
cartilage. Mechanical loading of articular cartilage generates a complex series of 
events, all of which are considered to affect chondrocyte metabolism. The changes in 
the physical environment following mechanical loading occur at different time points 
(ranging from milliseconds to hours) and are dependent on the magnitude and duration 
of loading. Although chondrocytes are widely regarded to respond to a range of these 
signals, their interaction in determining the overall cellular response is poorly 
understood. (Adapted from Urban, J. P. G., and Hall, A. C. (1994) The Effects of 
Hydrostatic and Osmotic Pressures on Chondrocyte Metabolism. In: Mow, V. C., 
Guilak, P., Tran-Son-Tay, R, Hochmuth, R. M., eds, Cell Mechanics and Cellular 
Engineering, ^  391-398, Springer-Verlag, New York).
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1.4.2. Aggrecan regulation by soluble mediators
A number of growth factors and cytokines modulate the synthesis of aggrecan 
and other extracellular matrix components in chondrocytes . Many of their effects have 
been determined from explant and cell culture experiments rather than in vivo studies, 
therefore interpretation of chondrocyte responses is limited because the experiment 
does not reflect the true physiological conditions. However, these studies have 
provided a basic understanding of the biochemical factors that regulate the catabolic 
and anabolic processes in chondrocytes which are necessary for cartilage homeostasis.
Interleukins l a  and 1(3 (IL -la and IL-lp) are proinflammatory cytokines that
promote articular cartilage degeneration. They stimulate prostaglandin production and 
induce expression of matrix metalloproteinases, including collagenase and 
stromelysin, which degrade aggrecan and other extracellular matrix components. The 
exact role of EL-1 in osteoarthritis has not been determined, but it has been shown to 
promote OA-like degeneration of articular cartilage in in vitro and in vivo studies. For 
example, incubation of cartilage explants with IL-1 promotes increased proteolytic 
cleavage of aggrecan core protein in the ECM (Ratcliffe et al., 1986). IL-1 is also a 
potent inhibitor of aggrecan synthesis (Tyler et al., 1985; Hardingham et al., 1992b). 
Further studies have shown that EL-1 does not affect post-translational events in 
aggrecan synthesis such as glycosylation and secretion (Benton and Tyler, 1988) but 
steady-state aggrecan (and link protein) mRNA levels have been shown to be 
suppressed dose-dependently in chondrocytes treated with IL-1 (Ratcliffe et al, 1996). 
These findings suggest that IL-1 regulates synthesis of aggrecan and other matrix 
molecules by transcriptional and/or translational mechanisms.
Tumour necrosis factor alpha (TNFa) is another inflammatory cytokine found
to have similar effects on articular cartilage metabolism. TNFa promotes proteoglycan
degradation in chondrocytes and cartilage expiants (Shinmei et al., 1991) and also 
inhibits proteoglycan synthesis (Saklatvala, 1986; Hardingham et al., 1992b) but its
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effects are less potent than IL-1 (Benton and Tyler, 1988). Increased levels of TNFa
have been observed in osteoarthritic synovial cells (Brennan et ah, 1989) chondrocytes 
(Shinmei et ah, 1991) and cartilage (Venn et ah, 1993) compared with normal, 
suggesting that this cytokine is involved in pathological cartilage degeneration.
TNFa has also been shown to suppress aggrecan synthesis at the level of
mRNA expression in chondrocye cultures (Dodge et al., 1998). Furthermore, its
inhibitory effect is potentiated by another cytokine, IFNy. Both cytokines inhibit
aggrecan mRNA levels to a greater extent than either one alone, and reduce the rate of
transcription of the aggrecan gene (Dodge et al., 1998). However, the effects of IFNy
on proteoglycan metabolism, and its role in joint inflammation are not well defined.
Despite its ability to suppress aggrecan synthesis, IFNy also antagonizes IL-1
mediated degradation of proteoglycan in cartilage explants and chondrocytes (Andrews 
et al., 1989) suggesting that it has a role in regulating the inflammatory response in 
articular cartilage.
Peptide growth factors also regulate the growth and synthetic processes of 
chondrocytes. They have also been implicated in cartilage damage and repair, and 
differentiation of chondrocytes from mesenchymal cells in the early embryo (Hill and 
Logan, 1992). The most studied growth factor classes are the fibroblast growth factors 
(FGF), the insulin-like growth factors (IGF-1) and transforming growth factor-beta
(TGFp). The effects of these factors on cartilage and chondrocyte biosynthetic activity
have been investigated under different culture conditions in order to understand their 
role in cartilage metabolism, development and disease.
Basic fibroblast growth factor (bFGF), epidermal growth factor (EGF) and 
platelet derived growth factor (PDGF) are known to promote mitogenic effects in 
articular cartilage (Kato et al., 1982; Osborn et al., 1989). These factors have also 
been reported to modulate the effects of inflammatory cytokines. In chondrocyte 
cultures, FGF potentiates the EL-1-mediated induction of protease activity
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(Chandrasekhar and Harvey, 1988&, In contrast, PDGF has an antagonistic effect on 
the action of IL-1, by inhibiting its suppression of proteoglycan synthesis (Harvey et 
al., 1993).
IGF-1 is considered to be a major regulator of proteoglycan synthesis in 
articular cartilage. It has been shown to modulate DNA and proteoglycan synthesis in 
immature and adult cartilage explant culture, and was identified as the major 
component of serum responsible for maintaining steady-state proteoglycan levels 
(Mcquillan et al., 1986b). IGF-1 is also thought to maintain the chondrocyte 
phenotype in the later stages of chondrocyte differentiation during development by 
promoting extracellular matrix synthesis (Malemud, 1993). It has been suggested that 
IGF-1 maintains elevated levels of proteoglycans by differential modulation of 
anabolic and catabolic pathways (Luyten et al., 1988) and this is influenced by the 
presence of other mediators. For example, IGF-1 antagonizes the catabolic effects of 
interleukin-1 by decreasing proteoglycan degradation in the ECM (Hardingham et al., 
1992b) and inhibiting its suppression of proteoglycan synthesis (Tyler, 1989). IGF-1 
also acts synergistically with other growth factors such as EGF and bFGF, promoting 
a stimulation of proteoglycan synthesis to levels greater than each factor used 
individually (Osborn et al., 1989).
TGFP is another growth factor that has been studied extensively, and has been
implicated in promoting chondrocyte differentiation, as detected by immunolocalization
studies of mouse embryos (Heine et al., 1987). TGF-P also promotes expression of
the chondrocyte phenotype in rat muscle mesenchymal cells (Seyedin et al., 1986).
Explant studies with adult cartilage have shown that as with IGF-1, TGFP sustains
proteoglycan synthesis by stimulating synthesis and reducing catabolism (Morales and 
Roberts, 1988). However, the extent of stimulation may vary with the age and source 
of cartilage (Hardingham et al., 1992b). Cell culture conditions also affect the
chondrocyte response to TGFp. Studies have found that increasing the seeding density
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of monolayer cells (Ballock et al., 1993) and culturing in a three-dimensional matrix 
enhances TGFp-induced stimulation of proteoglycan synthesis (Bujia et al., 1996).
These observations suggest that cell shape may determine how chondrocytes respond 
to growth factors.
TGFp may also play an important role in cartilage repair. It has been shown to
modulate the inflammatory response by inhibiting IL-1-mediated protease induction 
and suppression of proteoglycan synthesis (Chandrasehkar and Harvey, 1988$. In 
vivo studies have demonstrated that it accelerates the healing of fracture wounds 
(Bolander, 1992) and osteoarthritic lesions (Bradham and Horton, 1998) by
promoting the phenotypic expression of chondrocytes. Therefore, TGFp may be
required to initiate matrix synthesis following inflammation in injured connective 
tissues.
The interplay of growth factors and cytokines complicates the understanding of 
the underlying mechanisms that control aggrecan regulation in chondrocytes. Analysis 
of transcriptional regulation of chondrocyte-specific genes such as aggrecan can 
provide a more detailed understanding of how chondrocytes respond to their 
environment. The information gained from characterising the gene structure and 
flanking regions of aggrecan is essential for analysis of gene regulation.
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1.5. Aggrecan gene structure and preliminary analysis of regulatory 
regions
1.5.1. Gene structure
The highly organized structure of aggrecan is also reflected at the gene level. 
The complete structure of the aggrecan gene with respect to intron-exon organization 
has been determined in rat (Doege et ah, 1994) human (Valhmu et ah, 1995b) mouse 
(Watanabe et ah, 1995) and chicken (Li and Schwartz, 1995). Comparison of the gene 
structures between species shows that gene organization is almost identical (table 4). 
The genes are very large and contain 18-19 exons within a genomic region of more 
than 40 kb. In each case the exons of the aggrecan gene correspond to domains of the 
protein core, whereby single exons or groups of exons code for individual protein 
domains (figure 1-e). Nucleotide sequence comparisons between the mouse and other 
species indicate that G l, G2 and G3 domains are the most highly conserved, while the 
KS and CS domains are less well conserved (Li and Schwartz, 1995). The individual 
domains of aggrecan also show high sequence homology with proteins that have 
related functions. For example, the Gl domain shares high sequence homology with 
other hyaluronan-binding proteins including link protein versican and brevican (Li and 
Schwartz, 1995; Valhmu et al., 1995b). These observations strongly suggest that the 
aggrecan gene has evolved via modular assembly of individual protein domains. The 
protein-coding exons of aggrecan are flanked by non-coding sequences or untranslated 
regions; in the human gene these regions correspond to exon 1 and the 3’ end of exon 
19.
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Feature Mouse Rat Human Chick
Number of exons 18 18 19 18?
Genomic size =61 Kb >65 Kb >40Kb >30 Kb
Intron 1 size >21 kb =30 kb >13 kb >8kb
Exon 1 untranslated? Yes Yes Yes Yes
(5’UTR)
Exon(s) encoding:
Signal peptide 2 2 2 2
G l 3-6 3-6 3-6 3-6
IGD 7 7 7 7
G2 8-10 8-10 8-10 8-10
KS 11 11 11/12 11
CS 12 12 12 12
G3 13-17 13-17 13-18 Not
determined
Exons containing 18 18 19 Not
3’untranslated region determined
(3’UTR)
Exon 12 size 3482 bp 3471 bp 4224 bp 3216 bp
(Chondroitin Sulphate
domain)
EGF1 domain present No No Yes Not
in aggrecan mRNA (pseudoexon) (pseudoexon) determined
Table 4. Genomic organization of the aggrecan gene. The intron-exon 
organization of the aggrecan gene is almost identical between species and shows 
distinct correlation with the individual protein domains (see also figure 1-e).
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Figure 1-e. The genomic structure of the human aggrecan gene correlates with 
individual protein domains. A The intron-exon organization of the aggrecan 
gene. The filled bars represent coding exons and the open bar represents non­
coding exon 1 (also known as the 5’ untranslated region; 5’UTR). The introns are 
shown as lines. B Schematic diagram of the protein domains of the aggrecan core 
protein. The protein domains are encoded by single exons or groups of exons (see 
also table 4). (Adapted from, Valhmu, W. B., Palmer, G. D., Rivers, P. A., Ebara,
S., Cheng, J-F., Fischer, S., and Ratcliffe, A. (1995) Structure of the human 
aggrecan gene: exon-intron organization and association with the protein domains. 
Biochemical Journal 309, 535-542)
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The promoter of the aggrecan gene has also been characterized in rat (Doege et 
al., 1994), mouse (Watanabe et al., 1995), chick (Pirok et al., 1997) and human 
(Valhmu et al., 1998a). The promoters do not appear to be well conserved between 
species but share common structural features characterisitic of type II eukaryotic 
promoters. These include the lack of classical TATA and CCAAT nucleotide motifs, a 
high G/C content, and the presence of overlapping SP-l/AP-2 transcription factor 
binding sites around the transcription start site. The rat, mouse, and chick genes also 
have multiple transcription start sites. The human promoter contains a number of 
potential transcription factor binding sites that may confer responsiveness to external
factors such as cytokines and mechanical stress. Motifs for NF-kB, cis platelet derived
growth factor (PDGF), and multiple shear stress response elements (SSRE s) are 
located in the 701 bp promoter and exonl (5’UTR). SSRB's have been shown to 
modulate activity of the PDGF-B chain promoter (Resnick et al., 1993) and the 
monocyte chemotactic protein-1 (MCP-1) promoter (Shyy et al., 1995) in response to 
fluid-shear stress, and may therefore play in important role in regulating aggrecan gene 
expression in response to mechanical forces.
1.5.2. Transcriptional regulation of the aggrecan gene
Evidence suggests that only one aggrecan gene exists in the genome. 
Chromosome mapping studies have localized it to chromosome 15q26 in humans 
(Korenberg et al., 1993; Just et al., 1993) and chromosome 7 in mouse. Further 
evidence for a single aggrecan gene is demonstrated by the identification of the same 
mutation in aggrecan mRNA from the cartilage, notochord and brain of nanomelic 
chickens (Domowicz et al., 1995; Domowicz et al., 1996). Consequently, functional 
studies have been performed in order to identify elements that are involved in the 
transcriptional regulation of the aggrecan gene in response to developmental and cell- 
specific signals. A detailed deletion analysis of the aggrecan promoter region in the 
chick (Pirok et al., 1997) identified silencing elements upstream of -700 nucleotides
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that correspond to cartilage-specific silencers also identified in the Col 2A1 promoter 
(Savagner et al., 1990). In addition, a chondrocyte-specific enhancer region was 
identified near the transcriptional start site, that contains SP-l/AP-2-like sequences. A 
similar analysis has been performed in the rat promoter (Doege et al., 1999) and 
regions that appear to have chondrocyte-specific activity were identified in the 
promoter and exon 1.
In the mouse aggrecan gene exon 1 has been implicated in mediating 
developmental expression of aggrecan, by binding to the scleraxis transciption factor 
(Liu et al., 1997). Scleraxis is a basic helix-loop-helix protein expressed in 
mesenchymal cells and sclerotomes during chondrogenesis (Cseijesi et al., 1995). 
Although the function of scleraxis has not been determined, it was found to promote 
expression of chondrocyte-specific genes including aggrecan in osteoblasts. Deletion 
analysis and electromobility shiftassays (EMSA’s) demonstrated that scleraxis 
upregulates transcriptional activity by binding to an E-box located in exon 1 of the 
mouse aggrecan gene (Lui et al., 1997). Similar studies with the mouse proalphal
(al )  II collagen promoter showed that the Sox-9 transcription factor promotes
chondrocyte-specific expression in transgenic mice (Lefebvre et al., 1996, 1997). 
Sox-9 is expressed in mesenchymal condensations during embryonic development and 
considered to have a major role in chondrogenesis (Lefebvre et al., 1998). Thus the 
molecular mechanisms that promote chondrogenesis can be identified by functional 
characterization of chondrocyte-specific genes such as type II collagen and aggrecan.
The regulatory regions of the human aggrecan promoter have not been 
characterized, but functional studies have been performed with the 5’ and 3’ 
untranslated regions (5’UTR and 3’UTR). Both UTR’s downregulate activity of a 
cytomegalvirus promoter, and the effect of the 3’UTR was found to be chondrocyte- 
specific (Valhmu et al., 1995a, 1998a). Furthermore, the inhibitory effect of the 
5’UTR was found to be position-independent with respect to the CMV promoter, 
indicating that it contains elements that can modulate transcriptional activity.
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The effect of growth factors and cytokines in the regulation of aggrecan 
expression has been well studied, but it has not been determined whether these 
mediators regulate activity at the transcriptional level. However, it has been shown that 
the 5’UTR of the human aggrecan gene mediates suppression of cytomeglavirus 
promoter activity in chondrocytes in response to IL-1 (Valhmu et ah, 1996). 
Regulatory elements that confer responsiveness to cytokines and growth factors have 
been identified in the promoter regions of other cartilage matrix proteins (table 5). In 
several studies, these elements have been shown to form protein/DNA complexes with 
common transcription factors. A similar methodological approach can be used to 
identify the DNA-protein interactions that modulate aggrecan gene expression in 
response to biochemical factors.
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Promoter Soluble
mediator
Effect Cell type Response
element
Reference
human
biglycan
IL-6
TNFa
increase
decrease
various 
tumour cell 
lines
CTGGGA
(EL-6RE)
Ungefroren 
and Krull, 
1996
human 
collagen la2
TGFp
TNFa
increase
decrease
fibroblasts CGAGTCTA
(AP-1)
Chung et 
al., 1996
human
collagen H a l
IL-1
IFNy
decrease
decrease
chondrocytes Not determined Goldring et 
al., 1994
human
collagenase
TGFP decreaseincrease
fibroblasts
kératinocytes
TGAGCTA
(AP-1)
Mauviel et
al.,1993,
1996
human decorin IL-1
TNFa
increase
decrease
fibroblasts TGAGCTA
(AP-1)
Mauviel et 
al., 1996
human
interstitial
collagenase
(MMP-1)
FGF2 increase osteoblasts AGGATG/TGA
GTCA
(Ets/AP-1)
Newberry 
et al., 1997
rat interstitial 
collagenase
EL-1 increase chondrocytes GTGACTCAT
(c-jun)
Grumbles 
et al., 1997
human/rat link 
protein
glucocortic
oids
increase chondrocytes GGAAACATT
ATGTACT
(human
GRE)GGAACA 
TGGTGTTCT 
(rat GRE)
Rhodes and
Yanada,
1995
human
procollagen
a l
TGFp increase fibroblasts CTCCTCCTCC CC (SP-1)
Jimenez et 
al., 1994
human
perlecan
TGFp increase fibroblasts TGGCCN, 5G CC
lozzo et al., 
1997
Table 5. Regulatory elements of extracellular matrix genes that confer 
responsiveness to soluble mediators. Functional promoter studies have been 
performed with the 5’ flanking regions of genes that are known to be expressed in 
connective tissues including articular cartilage. The studies used deletion analysis to 
identify cis-acting elements that confer responsiveness to biochemical factors. Many of 
the studies also used electromobility shift assays (EMSA’s) to identify transcription 
factors that mediated the response, and competition binding studies to pinpoint the 
individual nucleotides involved in protein binding.
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1.6. Signal transduction in chondrocytes
Although the effects of growth factors, cytokines and mechanical stimuli on 
chondrocyte activity have been extensively studied, little is known about the 
intracellular signalling pathways that relay the extracellular stimulus to the cell nucleus. 
Studies on intracellular signalling have led to the elucidation of several membrane- 
associated and cytoplasmic regulatory molecules such as protein kinases that activate 
gene expression in response to specific extracellular signals. One such family of 
regulatory molecules are the mitogen-activated protein kinases (MAPKs). MAPKs 
comprise a group of serine/threonine protein kinases that initiate cellular processes 
such as proliferation, differentiation and development. The extracellular-regulated 
kinases (ERK-1/2) MAPKs were the first group of MAPKs to be identified, and were 
found to be activated in response to growth factors such as neurotrophic growth factor 
(NGF) and epidermal growth factor (EGF) (Boulton et al., 1991; Ahn et al., 1991). 
Other MAPK homologs including Jun N-terminal kinases (JNK)/stress-activated 
protein kinases (SAPK) and p38/RK/Mpk2 have since been identified through their 
ability to respond to distinct extracellular stimuli (Derijard et al., 1994; Kyriakis et al., 
1994; Han et al., 1994; Rouse et al., 1995).
Growth factors and cytokines are known to activate MAPKs in chondrocytes. 
ERK-1/2 MAPKs are activated in cultured chondrocytes in response to a broad range
of extracellular stimuli including EPS, IL-1, TNFa, IGF, and TGF(3 (Geng et al.,
1996). Interestingly IL-1 and TNFa are more potent activators of JNK (Geng et al.,
1996; Scherle et al., 1997) indicating that this isoform may be responsible for the 
induction of genes that mediate cartilage degeneration. Little is known about the role of 
MAPKs in the regulation of aggrecan gene expression in chondrocytes, but inhibition 
of ERK-1/2 MAPKs has been shown to reverse the downregulation of proteoglycan
synthesis by IL-1 and TNFa (Pratta et al., 1998). Since aggrecan synthesis in
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chondrocytes is regulated by many biochemical and mechanical factors it is of interest 
to determine which signalling pathways are activated in response to these stimuli.
The physical effects on chondrocytes generated by loading of articular 
cartilage, may also regulate chondrocyte activities via the activation of classic 
intracellular signalling pathways. In addition to their sensitivities to growth factors and 
cytokines, MAPKs are activated by physical stimuli such as UV light, heat shock and 
osmotic challenge (Berk et al., 1995). However, the intrinsic coupling of physical 
stimuli such as cell deformation, cell strain, fluid pressure and flow, and electrokinetic 
phenomena, has made the elucidation of mechanotransduction mechanisms in 
chondrocytes very difficult. In vitro cell culture models have been developed in order 
to investigate the effect of discrete physical stimuli on the biological responses of 
cultured cells (Usami et al., 1993; Hung and Williams, 1994). In chondrocytes, fluid- 
induced shear stress has been shown to increase the synthesis of glycosaminoglycans 
(Smith et al., 1995; Das et al., 1997), aggrecan (Malavivya et al., 1998) and IL-6 
(Mohtai et al., 1996), and induce changes in cell morphology (Smith et al., 1995). 
Furthermore, inhibitor studies have identified the ERK-1/2 MAPKs (Valhmu et al., 
1998b) phospholipase C (Das et al., 1997) and intracellular Ca2+ (Hung et al., 1998) 
as being involved in mediating the flow response. Mechanotransduction mechanisms 
have been more extensively characterized in vascular endothelial cells using similar cell 
culture models (Chien et al., 1998). Transcription factors such as AP-1, NF-kB, SP-1 
and EGR 1 have been identified in downstream signalling events, and shown to induce 
activity of endothelial cell genes by interacting with corresponding cis elements (Chien 
et al., 1998; Khachigian et al., 1995; Jalali et al., 1998; Sumpio et al., 1998). A 
similar analysis using regions of the aggrecan promoter can potentially identify the 
nuclear proteins activated by mechanotransduction in chondrocytes.
35
1.7. Hypothesis and Specific aims
Aggrecan expression is subject to regulation by environmental, developmental, 
tissue-specific signals. Identification and characterization of the regulatory elements of 
the human aggrecan gene are necessary first steps in addressing the molecular 
mechanisms through which the gene is regulated. A DNA fragment containing the 5’ 
flanking region of the aggrecan gene has been isolated, providing a basis for 
investigation of the transcriptional mechanisms of the human aggrecan gene. The 
proximal (701 bp) region of the human aggrecan gene has already been sequenced and 
found to contain a number of transcription factor motifs that may be important in 
regulating aggrecan gene expression. Previous transient transfection studies using 
luciferase reporter constructs have demonstrated regulatory activities with the 
untranslated regions of the human aggrecan gene in the presence of a cytomeglavirus 
promoter (Valhmu et al., 1995a, 1998a). The overall hypothesis of this project is that 
sequences both upstream and downstream of the transcriptional start site are essential 
for the regulation of aggrecan gene expression and respond to biochemical and 
physical stimuli. A series of similar functional studies using reporter constructs that 
contain the aggrecan promoter can be performed in order to further understand the 
molecular mechanisms that control expression of the aggrecan gene. Therefore specific 
aims of this study were to:
1. Sequence the upstream region of the aggrecan promoter and identify putative 
regulatory regions that may enhance or repress gene expression.
2. Determine the effect of the 5’ untranslated region (5’UTR) and upstream region on 
the regulation of aggrecan gene expression.
3. Identify sequences in the promoter and 5’UTR that respond to external factors, 
including soluble mediators (growth factors and cytokines) and mechanical 
stresses.
4. Identify the intracellular signalling mechanisms by which chondrocytes regulate 
aggrecan gene expression in response to environmental stimuli.
36
Chapter 2: MATERIALS AND METHODS
2.1. Sequencing of the human aggrecan distal promoter region
2.1.1. Subcloning of the distal promoter region
A clone containing 1.7 kb of uncharacterized aggrecan upstream genomic DNA 
was prepared, and used for sequencing and promoter activity studies. The upstream 
region of the human aggrecan gene was previously obtained by PCR using the human 
genomic PromoterFinder kit and protocols (Clontech Laboratories, Palo Alto, CA). An 
unsequenced 1.7 kb portion corresponding to the upstream aggrecan promoter region 
was removed from a pCR II TA cloning vector (Invitrogen Corporation, Carlsbad, 
CA) that also contained l.OSkb of previously sequenced aggrecan DNA (comprising 
the 0.7 kb proximal promoter and 0.35 kb exon 1). The 1.7 kb region was removed 
by digestion with Mlul (located in the PromoterFinder adaptor) and Ndel (located at - 
670 of the proximal promoter) and cloned into the Mlul/Ndel site of a luciferase 
reporter construct, pAGCl(-701)/5’UTR, that contained the proximal promoter and 
5’UTR(exon 1). This generated a clone that contained approximately 2.4 kb of 
aggrecan promoter sequence and the 5’UTR and was used as a template to sequence 
the distal 1.7 kb region of the aggrecan promoter (fig. 2-a).
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2.1.2. Design of sequencing primers
Primers were designed using the following criteria:
I. Sequencing primers were between 18 and 25 bp in length
II. The primers had 50 to 60% G+C composition to ensure efficient annealing to the 
template.
III. Runs of C’s and G’s and palindromic sequences were avoided where possible, in 
order to prevent potential mispriming.
IV. Regions of self-complementarity, particularly at the 3’ end of the primer, were also 
avoided.
V. The 3’ end contained a GC clamp, where at least two of the 3’ most nucleotides 
contained a G or C to ensure binding at the correct site.
Sequencing primers were synthesized by Oligos Etc (Wilsonville, Oregon). 
The distal region of the aggrecan promoter was sequenced using forward and reverse 
primers. Initially a vector forward primer was used to sequence the 5’ end, and a 
nested reverse primer in the 701 bp promoter region was used to sequence the 3’ end. 
New forward and reverse primers were designed with each new round of sequence 
(table 6).
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Primer name Primer Sequence
VF-1 5 ’ -TCTGCTTAGGGTTAGGCGTT-3 ’
VF-2 5’-CCAATATATGTTTCTTAGACT-3’
VF-3 5 ’ -GTGGCGCC ATCTC AGCTC ACTG-3 ’
VF-4 5’-TCAAGAATGGCCAACCACTG-3’
VX-2 5 ’ -CCTC ACCG AGGAGCTGGCTG-3 ’
VX-3 5 ’ -G AGCCC AAC AAGGTAAAT ATGG-3 ’
VX-4 5 ’ - A AGCTTCCTG ACCCTCTC ATTGG-3 ’
VX-5 5 ’ -GAGCGT ATTG AGTC AGGTCTG-3 ’
VX-6 5 ’ -GTTACTGGCCTC AATGCCTGG-3 ’
Table 6. Primers used to sequence the 1.7 kb distal region of the 
aggrecan promoter. VF primers are forward, VX primers are reverse.
The DNA template was purified using Wizard plus Midipreps DNA 
purification system (Promega Corporation, Madison Wisconsin) and submitted (with 
primers) to the Columbia University DNA Synthesis and Sequencing Facility for 
automated sequencing (Applied Biosystems, Foster City, CA).
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Figure 2-a. Sequencing strategy for the distal region of the aggrecan promoter.
The distal promoter region was subcloned into a reporter construct containing the 
proximal promoter region and 5’UTR of the human aggrecan gene, pAGCl(- 
701)/5’UTR. The newly generated construct was used as a template to sequence 
the distal 1.7 kb portion of the aggrecan promoter. New forward and reverse 
primers were designed with each new round of sequence. Overlapping sequence 
were aligned using a nucleotide alignment programme at the Whitehead Institute 
for Biomedical Research website (www.-genome.wi.met.edu). The construct was 
found to extend to -2368 nucleotides upstream of the transcription initiation site 
and was called pAGCl(-2368)/5’UTR.
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2.1.3. Sequence analysis
Nucleotide sequence similarity searches were performed using the BLASTn 
programme at the National Center for Biotechnology Information (NCBI) website 
(www.ncbi.nlm.nih.gov). The programme performs nucleic acid sequence alignments 
with all GenBank sequence databases (Altschul et al., 1997). A gapped BLAST search 
was performed so that minor sequence deletions and insertions did not affect the 
alignment results. A significance threshold limit of E<1 was set so that only high 
scoring alignments with low E (expect) values were reported. This value specifies the 
number of matches with a given score that are expected in a search of a particular 
database, purely by chance. The BLASTn programme was also used to search a 
eukaryotic promoter database (EPD) and a database containing select Alu repeats, both 
available at the NCBI website.
The nucleotide sequence of the upstream promoter region was scanned for 
transcription factor binding regions using the Matlnspector programme and Madrid 
library of consensus patterns (Quandt et al., 1995) at the Baylor College of Medicine 
Search Launcher Site (www.hgsc.bcm.tmc.edu/SearchLauncher/). The programme 
contained adjustable parameters that determine the specificity of the search results. The 
core similarity value specifies the level of significance associated with the consensus 
sequences selected from the transcription factor matrix library, to be used in the 
search. This value was set to 0.9, from a range of 0 to 1.0. A core similarity of 1 
indicates that only transcription factor motifs that represent the “core sequence” are 
used in the search. Highly significant sequence matches were reported by setting the 
matrix similarity value to 0.9, a perfect matrix similarity of 1 occurs if the candidate 
sequence corresponds to the most conserved nucleotide at each position of the 
consensus sequence.
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2.2. DNA manipulation
Genomic clones were digested, purified and religated to form new recombinant 
DNA clones for study. The strategies used were dictated by the genomic sequence of 
the aggrecan 5’ flanking region and the restriction enzyme profiles of the aggrecan 
sequence and the cloning vectors used. Protocols were followed according to the 
suppliers instructions, with some modifications and are now briefly described.
2.2.1. Agarose gel electrophoresis
Plasmid clones and DNA fragments were resolved on 0.5 to 2% agarose gels 
(Life Technologies, Gaithersburg, MD) prestained with 0.5jig/ml ethidium bromide.
DNA samples were mixed with gel-loading buffer containing either 0.25% 
bromophenol blue or 0.25% xylene cyanol. Gels were run in the presence of 0.5X 
tris-taurine ETDA (TTE) buffer at 150 V using a electrophoresis power supply 
500/400 (Pharmacia Biotech, Uppsala, Sweden). Gel photographs were taken using 
C-80 Epi-illuminator UV darkroom (Ultra-Violet Products, Upland CA) and the Scion 
Image software package (Scion Corporation, Frederick, MD).
2.2.2. Restriction digestion
Restriction enzyme digestions were performed using the reagents and 
protocols from either Promega, New England Biolabs (Beverly, MA), and Boehringer
Mannheim (Indianapolis, LN). To prepare DNA fragments for cloning, 5 to 10 gg of
construct DNA was digested with 5 to 10 units of enzyme in 20 gl volumes for > 2 hrs
at the required temperature. Digested fragments were resolved on ethidium bromide- 
stained agarose gels with Ikb and 123 bp molecular size markers (Life Technologies). 
The desired fragments for cloning were identified by size under ultraviolet light and 
excised with a scalpel blade.
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2.2.3. DNA purification
DNA was purified prior to ligation, from high-salt buffers, nucleotides, 
enzymes and agarose by a silica based matrix method using the Geneclean III kit 
reagents and protocols (BIO 101 Inc. La Jolla, CA). The protocol is modification of 
the method first reported by Vogelstein and Gillespie (1979). DNA mixtures were 
incubated with 6 to 10 ul of glassmilk™ in the presence of 6M sodium iodide at room 
temperature for 10 minutes. The glassmilk-DNA was then pelleted and washed three
times in 70% ethanol. Purified DNA was eluted from the silica in 12 to 20 pi volumes 
using low-EDTA TE buffer.
2.2.4. Blunt ending of DNA fragments
For the preparation of some DNA constructs, the 5’ overhangs of restriction 
digested fragments were blunt ended with T4 DNA polymerase (Life Technologies). 
The reaction conditions used for generating blunt ends were based on the methods
described by Challberg and Englund (1979), and Deen et al. (1983). Typically, 1 pg
to 5 pg of DNA was incubated with 10 units of polymerase for 30 minutes at 11°C.
The polymerase was heat inactivated in a 65°C waterbath for 15 minutes, and DNA 
was purified by Geneclean.
2.2.5. Ligation, transformation and screening recombinant clones
Blunt-end and cohesive-end ligations were performed using Life Technologies 
T4 DNA ligase. The cloning conditions used were based on those recommended by 
the manufacturer and Sambrook et al. (1989). The insert to vector molar ratio was 2:1 
for each ligation. Ligations were performed overnight using 0.2-1 units of ligase at 
4°C for cohesive-ends and 2.5 units of enzyme at room temperature for blunt-ends.
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The ligation mixes were transformed using premade, high effeciency JM109 
competent cells (Promega). Plasmid DNA was transformed into bacteria using a 
protocol based on the heat shock method developed by Mandel and Higa (1970), and 
Cohen et al. (1972). The transformation mixes were plated onto LB agar plates
containing 100 |Lig/ml ampiciln and incubated overnight at 37°C.
Bacterial colonies were isolated and cultured in LB media containing 100 Jig/ml
ampicillin for 6-12 hrs in a 37 °C shaker bath. Plasmid DNA was isolated using the 
Qiagen Miniprep kit (Qiagen Inc, Valencia, CA) and protocol for rapid isolation of 
plasmid DNA. Recombinant clones were digested with the appropriate restriction 
enzymes and resolved by agarose gel electrophoresis to confirm insert size. Positive 
clones were then grown in 60 ml culture volumes in order to generate larger quantities 
of DNA. Plasmids were purified using the Wizard Plus Midipreps DNA Purification 
System (Promega, Madison, WI). Glycerol stocks were made by mixing an aliquot of 
cell culture 1:1 with 50% glycerol and freezing at -80 °C.
2.2.6. Plasmid preparation
Plasmid constructs were purified from bacterial cultures by the Wizard Plus 
Midipreps DNA Purification System (Promega). The protocol is a modification of the 
alkaline lysis procedure reported by Bimboim and Doly (1979), and uses a silica based
resin to purify plasmid DNA. Plasmids were eluted from the resin using 300 jul of
low-EDTA TE buffer and quantified by measuring the OD260 using a UV160U 
spectrophotometer (Shimadzu Scientific Instruments Inc., Columbia, MD) or by 
agarose gel electrophoresis.
For gel quantification purified plasmids were serially diluted 10-, 100- and 
1000-fold in water and linearized by restriction digestion with BaniRl for 1 hr at
Sû/yi/C
37°C. The 10 pi digest of each promoter construct, and a set ofNinearized (J) X174 
plasmid standards of known concentration were electrophoresed on a 1 % agarose gel
44
prestained with 0.5 Jig/ml ethidium bromide. DNA bands were quantified from a
digital image of the agarose gel using a C-80 Epi-illuminator UV darkroom and the 
Scion Image software package. Plasmid concentration was calculated from the
regression coefficient of the linear portion of the (j)X174 standard curve.
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2.3. Preparation of aggrecan promoter-Iuciferase constructs
In order to perform functional promoter studies, aggrecan promoter fragments 
were isolated from the PCR II TA cloning vector (Invitogen Corporation, Carlsbad, 
CA) and subcloned into luciferase reporter constructs.
Reporter plasmids containing the proximal 701 bp promoter with and without 
the 5’UTR(exon 1) of the human aggrecan gene were previously made by co-workers 
as described by Valhmu et al. (1998a). Briefly, the clones were made by digesting a 
pCR II cloning vector (containing the promoter) with Mlul and BsrB 1. The fragment 
(corresponding to -701 to +25 of the aggrecan gene) was then subcloned into to the 
BsrQ 1 site of a construct containing the human aggrecan 5’UTR (pHA/5’UTR), 
replacing a CMV promoter. The newly generated construct contained the aggrecan 
promoter and 5’UTR adjacent to a luciferase reporter gene, pAGCl(-701)/5’UTR. 
Similarly, pAGC 1 (-701/+25) was made by cloning the same Mlul/BsrBl promoter 
fragment (-701 to +25) in the M lul/ BamHl site of a luciferase reporter vector 
(pLUCneo), immediately upstream of the luciferase gene.
To more closely identify regulatory regions of the aggrecan proximal promoter 
region, pAGC1 (-701 )/5 ’ UTR was used as a template to generate a series of constructs 
with sequential promoter deletions using endogenous restriction enzymes (figure 2-b). 
The pAGC 1 (-701 )/5’UTR construct was digested with either Pstl, AccIII, or Apal to 
generate 5’ promoter deletions at -451, -179 and -52 respectively. The ends were then 
blunted with T4 DNA polymerase and digested with with BamHl (located at the 
downstream end of the 5’UTR) and cloned into a promoterless luciferase reporter 
vector generated from pAGCl(-701)75’UTR by Mlul!BamHl digestion. The newly 
generated constructs were p AGC 1 (-451 )/5 ’ UTR, p AGC 1 (-179)75 ’ UTR, and 
p AGC 1 (-52)75 ’ UTR (fig. 2-b). A second -52 deletion construct was also made by 
Apal/BamHl digestion using pAGCl (-7017+25) as a template, to produce pAGCl(- 
527+25).
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Figure 2-b.
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Figure 2-b. Preparation of human aggrecan promoter deletion clones from  
-701 to -52. A series of 5’ proximal promoter deletions were made by digesting 
p AGC 1 (-701 )/5 ’ UTR with endogenous restriction enzymes and blunting the ends with 
T4 DNA polymerase. A second digestion with BamHl (located at the downstream end 
of the 5’UTR) created promoter-5’UTR fragments which were cloned into an empty 
luciferase reporter vector with a compatible BamHl end. A second -52 bp deletion 
construct was made by cloning a -52/+25 promoter fragment, obtained by 
Apal/BamHl digestion of pAGCl(-701/+25) into the same luciferase vector (not 
shown in figure).
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A larger promoter-Iuciferase construct was made containing an additional 1.7 
kb of the aggrecan promoter. The construct [pAGCl(-2368)75’UTR] was prepared as 
described in fig. 2-a. The M lul/ Ndel fragment corresponding to the 1.7 kb upstream 
region of the aggrecan promoter was also cloned into the Mlul/Ndel site of pAGCl(- 
7017+25) to generate pAGCl(-23687+25) (fig. 2-c).
In order to investigate the regulatory activity of the upstream region of the 
aggrecan promoter, another series of sequentially deleted promoter clones were made 
between -2368 and -701 using endogenous restriction enzymes (fig. 2-d). The largest 
construct containing the 5’UTR, pAGCl(-2368)75’UTR was used as a template to 
generate the set of deletions. Three clones were made by initially removing the 
upstream promoter 1.7 kb fragment by Mlul/ Ndel digestion. Subfragments were 
then made by cutting with either Apol, Bsgl or Bsu36l and separated by 
electrophoresis of a 1% agarose gel. The DNA fragments were then purified from 
agarose by Geneclean HI and blunt ended by T4 DNA polymerase. The blunt ended 
fragments were digested with Hindlïl, to generate a cohesive end, and ligated into a 
Mlul -blunted/77indUI digested pAGCl (-2368)75’UTR. This generated recombinant 
clones which were truncated to -1941, -1778 and -1508 (figure 2-d). Further 5’ 
deletions were made by digesting p AGC 1 (-2368)75 ’ UTR with M lul, and either 
Hindlll, or Kspl, and religating the blunted ends. This created promoter deletions of - 
1079, and -780 respectively.
A second 5’UTR deletion construct, pAGCl(-23687+213), was also made and 
used in later deletion studies by isolating the Mlul/BamH.1 2.7 kb promoter/5’UTR 
fragment from p AGC 1 (-2368)75’ UTR, and digesting with PpuMl to remove 162 bp 
from the 3’ end of the 5’UTR.
Reporter constructs were also made containing a minimal, heterologous, 
thymidine kinase (TK) promoter in order investigate the regulatory activity of the 
upstream promoter region. Initially, a thymidine kinase luciferase reporter vector was 
made by cloning a BglWHm<7ïïl-blunted TK promoter fragment from the pRLTK 
vector (Promega) into a luciferase reporter vector which had been digested with
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BgliVBamRX to remove the 2.7 kb aggrecan sequence. This construct, pTKluc+, was 
then modified to contain a portion of the upstream region of the aggrecan promoter . 
The 1.7 kb Mlu V Ndel upstream promoter fragment was cloned into the Bglll site of 
pTKluc+ by blunt end ligation to generate pAGCl(-2368/-670)TK.
All recombinant clones were sequenced at the vector/promoter junctions and 
digested with the appropriate restriction enzymes to confirm insert size and orientation.
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Figure 2-c. Preparation of 2.4 kb promoter clones. The distal 1.7 kb region of 
the human aggrecan promoter was cloned into two luciferase reporter constructs 
containing the proximal (701 bp) promoter region with and without the 5’UTR. 
This generated p AGC1 (-2368)75’ UTR and pAGCl (-23687+25) which were used in 
transfection studies. The p AGC1 (-2368)75’ UTR construct was also used as a 
template to sequence the distal region of the promoter.
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Figure 2-d. Preparation of deletion clones from -2368 to -701. Promoter 
deletions from -1941 to -1508 were made by generating truncated promoter 
fragments from pAGCl(-2368)/5’UTR using endogenous restriction enzymes and 
cloning them into a luciferase vector. Similarly, a 5’UTR deletion construct 
pAGCl(-2368/+213) was made by cloning the Mlul/PpuMl fragment of pAGCl(- 
2368)/5’UTR into a promoterless luciferase vector. The -1079 and -780 deletion 
constructs were made by digestion with M /m land the appropriate restriction 
enzyme, and then religating the digested products. The restriction enzymes used to 
prepare these constructs are shown, and the ones in bold type generated the 
deletion endpoints.
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2.4. Cell Culture
2.4.1. Cell preparation
Chondrocyte and fibroblast monolayer cultures were prepared in order to 
measure aggrecan gene expression by transient transfection of promoter-reporter gene 
constructs or assaying aggrecan mRNA levels by quantitative reverse transcriptase 
(RT) PCR.
Primary bovine articular chondrocytes were harvested from the carpo-
oktttmec/ frow ow Cikk&foir
metacarpal joint (wrist) of 4 to 6 month old calves^within 6 hours of sacrifice. Articular 
cartilage specimens were diced into approximately 1 mm3 chunks and rinsed in fully 
supplemented Dulbecco’s Modified Eagles Medium (DMEM) containing 10% FBS. 
To isolate chondrocytes, the chunks were digested with 25mg bovine testicular 
hyaluronidase type I-S to a final concentration of 0.5mg/ml in DMEM at 37°C. After 
30 minutes, 25 ml of hyaluronidase/DMEM solution was removed and replaced with 
clostridial collagenase type II (Sigma) again at 0.5 mg/ml in DMEM. The digestion 
was continued overnight at 37°C. Chondrocytes were separated from digested matrix
components by sterile filtration through a 30 jiM nylon mesh. The cells were pelleted 
fck<
4in a 4°C benchtop clinical centrifuge at 3000 rpm for 10 minutes. Cell pellets were 
rinsed and repelleted in DMEM and resuspended in 10 to 20 ml of mediondepending on 
the pellet size. The cell number was calculated using a haemacytometer, and cell 
viability was determined by trypan blue exclusion. Chondrocytes were plated at a 
density of 1 x 106 cells per 60 mm dish, or 3 x 105 cells per 35 mm dish, depending 
on the transfection study. The desired confluency for transient transfection or mRNA 
assay was 70-80%. All cells were incubated in a 5% C 02 incubator with maximal 
humidity until experiments.
Promoter constructs were also transfected into COS and NIH3T3 fibroblast 
cell lines to determine cell specific activity of the aggrecan promoter. The cell lines
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were obtained from American Type Culture Collection (Manassas, VA) and expanded 
and grown to confluency on 60 mm dishes and passaged with 5 ml/dish 0.1X 
Trypsin-EDTA solution (Fisher). The Trypsin was inactivated by incubation with 10 
volumes of fully supplemented DMEM containing 10% FBS. After counting, the cells 
were plated on 60 mm dishes at 2 x 105 cells per 60mm dish so that 30 to 60% 
confluency would be reached at the time of transfection.
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2.4.2. Transient transfection
Promoter constructs were expressed in primary monolayer chondrocytes by 
transient transfection using the calcium phosphate coprecipitation method (Graham and 
van der Eb, 1973). The method is based on the formation of a DNA/calcium phosphate 
coprecipitate which facilitates the entry of DNA into cultured cells by endocytosis. 
Short-term transient transfections were preferred, as chondrocytes have been shown to 
decrease phenotypic expression of aggrecan and type II collagen in long term 
monolayer cultures (Benya and Shaffer, 1982; Hering et ah, 1994).
All DNA used for transfection was purified from bacterial cultures by the 
Wizard Plus Midipreps DNA Purification System (Promega) and quantified against 
plasmid standards of known concentration on agarose gels. Chondrocyte monolayer 
cultures were prepared form cartilage explants as described previously, 24 hours prior 
to transfection. The cells were incubated with fresh culture media 3 hours before the 
transfection experiment. The transfection was performed using the ProFection calcium 
phosphate mammalian transfection kit and protocols (Promega). For each transfection 
mix, a solution containing the promoter-Iuciferase construct, 2M calcium chloride,
water and a beta-galactosidase cotransfection plasmid (pCMV/pgal), was prepared. To
form a precipitate, the calcium chloride-DNA solution was added dropwise to an equal 
volume of 2X HEPES buffer and incubated at room temperature for 30 minutes. The 
transfection mix was then added to the cell culture dishes and incubated in a 37°C C 02 
incubator for 48 hrs. The culture medium was changed 12-16 hours after transfection
to minimize the exposure time to calcium phosphate. For 35 mm dishes, 3 gg of each
promoter-Iuciferase construct and 0.75 gg of p-galactosidase were transfected. To
investigate cell-specific promoter activity, chondrocyte and fibroblast monolayer 
cultures were prepared and transfected in parallel.
After 48 h transfection, the growth media was removed from culture dishes 
and the cells were washed twice with ice cold Ca2+/Mg 2+-free phosphate-buffered
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saline (PBS). The cells were then lysed with a IX solution of Reporter Lysis Buffer 
(Promega) for 15 minutes at room temperature and dislodged from the plate using a 
cell scraper. The cell lysates were vortexed for 10-15 seconds and microcentrifuged 
for 10 minutes at 12000 rpm to remove cell debris.
Luciferase and p-galactosidase activities were determined by 
chemiluminescence assays using a LKB-Wallac liquid scintillation counter and the 
Promega luciferase assay system or the Tropix Galacto-Light p-gal assay kit (Tropix, 
Bedford, MA) respectively. For some experiments enzyme activities were determined 
from serially diluted luciferase and p-galactosidase protein standards. Luciferase
values were normalized to P-galactosidase values for each of the samples in all 
transfection experiments. Promoter activity was either expressed as units of activity 
(units luc/units p-gal) or as counts per minute (lue cpm/p-gal cpm x 1000).
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2.4.3. Quantitation of aggrecan mRNA levels
In order to measure aggrecan gene expression in response to biochemical 
stimuli mRNA levels were quantified from primary bovine monolayer chondrocyte 
cultures by the method of quantitative RT-PCR (Re et ah, 1995). This procedure 
allows the study of specific cartilage matrix components using gene specific primers 
and provides a more specific measurement of aggrecan gene expression than the 35S- 
Sulphate incorporation method.
Primary bovine monolayer chondrocytes were harvested from cartilage as
previously described, and plated on 35mm dishes at 4 x 105 cells per dish. After 48
hpS the cells were incubated with or without biochemical factors and maintained in a
tissue culture incubator for a further 24 hp£. Total RNA was extracted from each dish
using the RNAgents Total RNA isolation system (Promega) based on the method of
Chomczynski and Sacchi (1987). The isolated RNA was further purified using
RNeasy Kit silica-based spin columns (Qiagen) to remove residual DNA,
o
polysaccharide, glycosamhfglycans, and other potential cartilage contaminants. RNA 
yield was determined by measuring the OD260 (1 OD260 = 40 |ig/ml) and OD280.
A 10 |il volume of purified mRNA was reverse transcribed using oligo(dT)15
primers and Superscript II reverse transcriptase (Life Technologies) in a total volume
of 30 pi for 30 minutes at 37°C. The cDNA samples were then serially diluted 100-,
500-, and 2500-fold in low-EDTA TE buffer and amplified using gene specific, 
intron-spanning aggrecan primers (located at the 3’ end of the aggrecan cDNA) on a 
Perkin-Elmer DNA thermal cycler. Standards containing known copy numbers of 
plasmids with the insert of the target cDNA was amplified in parallel with the 
unknown cDNA samples.
A 20 pi volume of sample and standard PCR products were electrophoresed on 
a 2% agarose gel prestained with 0.5 pg/ml ethidium bromide. The PCR products
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were quantified from a digital image of the gel using a C-80 Epi-illuminator UV 
darkroom. The cDNA copy number (proportional to aggrecan mRNA level) was 
calculated from the regression coefficient of the linear portion of the standard curve.
The cDNA copy numbers were normalized per pg total RNA from each sample.
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2.4.4. Treatment with biochemical factors
2.4.4.1. Cytokine treatment of chondrocytes
The effect cytokines on the regulation of aggrecan gene expression was 
investigated by treating chondrocyte cultures with IL-1 and TNFoc. In transfection
experiments the growth media were removed 20 hours after transfection, and culture 
dishes were washed with IX Ca27Mg2+-free Phosphate buffered Saline (PBS) to 
remove residual FBS-containing media. After a 5 minute incubation, the PBS was 
replaced with fully supplemented DMEM containing 0.1% Bovine Serum Albumin
(BSA) and either IL-1 or TNFoc (Genzyme) at the desired concentration. Control
cultures were replaced with DMEM + 0.1% BSA only. The cells were incubated for a 
further 24 hrs before harvesting.
Untransfected cultures were also treated with cytokines in order to investigate 
their effect on aggrecan mRNA levels. Chondrocyte monolayer cultures were prepared 
and treated in parallel with transfected cultures. After 24 hrs cytokine treatment, the 
cultures were assayed for mRNA.
2.4.4.2. Treatment with signal transduction inhibitors
Cell cultures were treated with signal transduction inhibitors in a series of 
experiments that investigated the intracellular signalling pathways involved in the 
regulation of aggrecan gene expression by chondrocytes.
Aggrecan promoter activity and mRNA levels were measured in chondrocyte 
cultures incubated with the MEK-1 inhibitor, PD98059 (Calbiochem-Novabiochem 
Corporation , La Jolla, CA). PD98059 is a highly selective inhibitor of MEK-1 
activation and the MAP kinase cascade (Alessi et al., 1995; Dudley et al., 1995) (fig. 
2-e). PD98059 was added from a 50 mM stock in DMSO to chondrocyte cultures 24
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hrs after transfection, at a final concentration of 25 jiM (unless stated otherwise) in
growth media containing 10% FBS. Control cultures were incubated with media 
containing an equal volume of DMSO. The cells were incubated with inhibitor for a 
further 24 hrs before harvesting. Untransfected cultures were prepared and treated 
with PD98059 in parallel, and assayed for aggrecan mRNA levels.
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Figure 2-e. PD98059 selectively inhibits MEK-1 activation and the MAP 
kinase cascade. PD98059 is a small cell-permeant molecule that binds to inactive 
forms of MEK-1 and MEK-2 and prevents activation by upstream activators such 
as c-Raf. The drug prevents activation of MEK-1 and MEK-2 in vitro, with IC5Q
values of 2-7pM respectively (Alessi et ah, 1995). PD98059 (Calbiochem-
Novabiochem) was added to chondrocyte cultures to investigate the role of the 
MEK/ERK pathway in regulating aggrecan gene expression.
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Transfected chondrocyte cultures were also treated with a series of inhibitors 
from a tyrosine kinase inhibitor set (Calbiochem) to determine the role of specific 
tyrosine kinases in the regulation of aggrecan promoter activity (table 7). Chondrocyte 
cultures were treated with either Genistein, Tyrphostin B42 (AG 490), Tyrphostin AG 
1295 or Tyrphostin AG 1478 following transfection at the same time intervals as the 
MEK-1 inhibitor study. The final concentration of each inhibitor was determined by 
the IC50 values that cause selective inhibition of specific tyrosine kinases.
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Inhibitor Effects Reference
Genistein Broad range tyrosine kinase inhibitor. 
Inhibits EGFR and pp60v*src phosphorylation
(IC50=20-25 jliM). Also has minor effect on 
PKC and PKA (IC50>150pM).
Akiyama et al., 1987
Tyrphostin 
B42(AG 490)
Selective inhibitor of JAK-2. Meydan et al., 1996
Tyrphostin 
AG 1295
Highly specific inhibitor of PDGF (IC50 = 
0.5|iM). Inhibits EGF and HER-2 only at
IC50> 100 pM
Levitzki and Gezit, 
1995
Tyrphostin 
AG 1498
Highly specific and potent inhibitor of EGFR 
(IC50 > 3 nM). Inhibits PDGFR and HER 1-
2 only at IC50 >100 |iM).
Levitski and Gezit, 
1995
Table 7. Biological properties of tyrosine kinase inhibitors. Chondrocytes 
were treated with the compounds at concentrations that selectively inhibit various 
tyrosine kinases that are important in cellular signalling.
63
2.4.5. Mechanical stress of cultured chondrocytes
2.4.5.I. Osmotic shock of monolayer chondrocytes
The effect of the osmotic environment on aggrecan gene expression was 
investigated by subjecting transfected chondrocytes with growth media of different 
osmolality. Primary bovine chondrocytes were prepared and transfected as previously 
described. After 24 hours of transfection the growth media were aspirated, and the 
culture dishes were rinsed in Ca2+/Mg2+-free PBS to remove residual serum. 
Chondrocytes were then incubated with solutions of different osmolality for a further 
24 hours in a 37°C C 02 incubator. The solutions were prepared by diluting DMEM 
with water or adding increasing amounts of sucrose. The osmolality of standard 
DMEM was measured using an osmometer (Advanced Instruments Inc, Norwood, 
MA) and determined to be 0.36 Osm. The osmolality was then adjusted from standard 
DMEM to give a range of 0.09 to 0.68 Osm by dilution or sucrose addition.
In order to determine the effect of osmolality on cell size, digital images of 
chondrocytes subjected to osmotic shock were recorded using an epiflouresence 
microscopy system. The system consisted of an Olympus 1X-70 inverted microscope, 
DeltaRam high speed monochrometer, and a MicroMax 5-Mhz interline transfer chip 
camera (Princeton Instruments, Trenton NJ). Hoffman modulation contrast images 
were recorded using the Pentium II Workstation and Metafluor/MetaMorph software 
(Universal Imaging Corporation, NJ).
Non-transfected primary chondrocytes were cultured for 48 hours in serum- 
free DMEM (0.36 Osm) following harvesting. The cells were then placed under the 
microscope and the osmolality of the growth media was changed by dilution or 
addition of sucrose to yield a final osmolality of 0.18 Osm or 0.58 Osm. Digital 
images were recorded at regular time intervals for up to 24 hours. Cell size was 
determined by measuring the cell diameter of 6-8 cells from each image using the 
MetaMorph software and a lOx objective.
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2.4.5.2. Fluid induced shear stress of monolayer chondrocytes
A parallel-plate flow chamber was designed by coworkers for studying the 
effect of mechanical shear stress on cells (Hung et ah, 1995). The chamber consists of 
a Plexiglass block and a borosilicate slide containing cultured cells, which are 
connected by a screws and a Plexiglass lid separated by a retangular spacer of uniform 
thickness (figure 2-f). The chamber was used to introduce fluid flow over transfected 
monolayer chondrocytes cultured on slides, to determine the effect of flow on 
aggrecan promoter activity.
Chondrocytes were prepared from tissue as previously described and plated in 
two centrally positioned 1.8 cnf-circular wells formed by modified Flexiperm silicone 
wells (Heraeus, South Plainfield, NJ). Cells were plated on Permonox slides (NUNC) 
at density of 2 x 105 cells/well in 1ml culture medium. The slides were stored in sterile 
100-mm plastic petri dishes and incubated in a 5% C 02 incubator until experiments.
The wells were transfected 24 hrs after plating with Ipg of pAGCl(-2368)/5’UTR and
0.2 pg of cotransfecting p-galactosidase plasmid according to the transfection protocol
described previously.
At the end of the transfection period (48hrs) the Flexiperm silicone wells were 
removed from the slides without dislodging the cells and each slide was placed in a 
parallel-plate flow chamber. The slides were equilibrated for 10 minutes in the flow 
chamber. A roller pump (VWRbrand, South Plainfield, NJ) in a closed loop 
configuration was used to circulate 19.5 ml culture mediekthrough the flow chamber, 
generating a steady shear stress of 16 dynes/cm2 on the monolayer chondrocytes. The 
flow was applied for 2 hrs in a 37°C incubator. The flow rate was determined by a 
flow transducer (Flo-sensor, McMillan Co., TX). No-flow controls were performed 
by placing slides in a flow chamber for 2 hrs at 37°C without subjecting to flow.
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Chondrocytes were harvested immediately after flow and assayed for luciferase and (3-
galactosidase activity.
To role of the MEK/ERK pathway in mediating the flow response was 
investigated by incubating chondrocytes with 200 nM PD98059 24 hrs before flow.
t/M
The culture medizt circulated through the flow chamber also contained the inhibitor at 
the same concentration. PD98059-treated no-flow controls were also performed.
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Figure 2-f.
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Figure 2-f. Schematic of a parallel-plate flow chamber used to subject 
cultured chondrocytes to fluid shear stress. The flow chamber was designed 
to deliver a controlled flow of growth media to cells cultured on a slide under 
physiological conditions. The laminar flow rate was controlled by a pump, and the 
fluid flowed through the chamber through ports which were connected to cylindrical 
reservoirs. The geometry of the chamber enabled the wall shear stress acting on the 
cells to be determined as a function of the laminar flow rate and fluid viscosity. A flow 
transducer was used to adjust the flow rate. In the study, chondrocytes were 
transfected with pAGCl(-2368)/5’UTR and flowed for 2 hrs to generate a steady 
shear stress of 16 dynes/cm2.
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2.4.6. MAPK assay
A MAPK assay was performed in order to determine the effect of PD98059 on 
the phosphorylation status of ERK-1 and ERK-2 MAPKs in transfected chondrocytes.
2.4.6.1 SDS-PAGE
Protein samples were prepared for electrophoresis from monolayer 
chondrocyte cultures which were transfected according to the method described in 
section 2.4.2. After treatment with PD98059 for 24 hours, the cells were harvested in
IX reporter lysis buffer, and assayed for luciferase and p-galactosidase activity. The
remaining cell lysates were mixed with 2 volumes of reducing buffer containing 2% 
SDS to denature all proteins (Laemmli, 1970). The electrophoresis running buffer and
gels were prepared according to the Laemmli buffer system and 40 pi aliquots of each
sample were electrophoresed on a 12% SDS-PAGE gel at 35 mA/gel using the Bio- 
Rad Protein II electrophoresis system and protocol (Bio-Rad, Hercules, CA).
2.4.6.2 Protein transfer
After electrophoresis, the gel was equilibrated in %  of pre-cooledTowbin 
transfer buffer (Towbin et al., 1970). A standard Western blot to nitrocellulose was 
performed based on the method of Towbin et al. (1970), using the Bio-Rad plate 
electrode Trans-Blot apparatus and protocol. The transfer was performed overnight at 
15 V using a Super Cooling Coil to prevent overheating.
2.4.6.3 MAPK detection
The blots were analysed for the phosphorylation status of extracellular signal- 
regulated kinases 1 and 2 (ERK-1/2, and also known as p44 and p42 MAP kinases) 
using the reagents and protocols of the PhosphoPlus MAPK antibody kit (New
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England Biolabs, Beverly, MA). The blots were probed with phosphospecific
&A h C P - lu tk e d  (UvK-f<tbb*tk sec o n d ^ fji A r -h b o c ty .
polyclonal antibodies and^mmune complexes were detected by chemiluminescence
using the Phototope -HRP Western Blot Detection Kit(New England Biolabs). The 
filters were exposed to Biomax MR-2 x-ray film (Eastmann Kodak Company, 
Rochester, NY) for up to 60 mins and autoradiographs were digitized and quantified 
using a CCD camera based gel documentation system (UVP Inc., Upland CA). The
intensities of the phosphorylated MAPK bands of each sample were normalized to p- 
galactosidase activity.
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Chapter 3: SEQUENCE ANALYSIS OF THE DISTAL REGION OF 
THE HUMAN AGGRECAN PROMOTER
3.1. The sequence of the distal region of the human aggrecan promoter
The proximal 701 bp region of the human aggrecan promoter was previously 
sequenced and published (Valhmu et ah, 1998a). This promoter region was also 
previously cloned into a luciferase reporter construct containing the 5’UTR (exon 1) of 
the human aggrecan gene, to generate a construct, pAGCl(-701)/5’UTR, to be used in 
functional studies.
A 1.7 kb DNA fragment corresponding to a distal portion of the human 
aggrecan promoter was isolated from a genomic clone and subcloned into pAGCl(- 
701)/5’UTR, and sequenced in forward and reverse orientation (fig. 2-a). An 
additional 1667 bp of human aggrecan promoter was sequenced and a larger promoter 
clone now contained 2368 bp of promoter and the 5’UTR [pAGCl(-2368)/5’UTR]. 
The sequence of the distal promoter region was then scanned for regions of homology 
with other genomic sequences using search programmes at the National Centre for 
Biotechnology Information web site (www.ncbi.nlm.nih.gov). The sequence was also 
analyzed for potential transcription factor binding sites using the Matlnspector 
programme (Quandt et ah, 1995) at the Baylor College of Medicine Search Launcher 
site.The sequence of the distal region of the human aggrecan promoter is presented in 
figure 3-a.
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- 2 3 6 8  AAAGTGTCCAAATGCGTTGCCATTATCCTGGGTTTTTTGTATCCTTTAGG - 2 3 1 9
- 2 3 1 8  GCTAGGGAGTGTGAATTCATACCANCCTGTACTCCAATCCCATTCACTAC - 2 2 6 9
- 2 2 6 8  CTTGATGGCCTCTGAATCTTGGTTTCTTAGTGTGTAAATGGGAATGGCAT - 2 2 1 9
- 2 2 1 8  CCATCTGAGAGGCTGCTGTACCAAGCAGCATCTGACACATAATAGGTGCC - 2 1 6 9
AP-1
- 2 1 6 8  CAATATATGTTTCTTAGACTCATTACAAAACCAGATGATCAATAAACATT - 2 1 1 9
- 2 1 1 8  TGTTCCCTTCAATACAAAGATAAATCGCCTAATTAATATTTGCCCTTGAC - 2 0 6 9
GATA-1
- 2 0 6 8  CTGTTCTTCATTAACCCCACCTGCCCTAGGATGAATGTTGACATGAACCC - 2 0 1 9
- 2 0 1 8  ATTTTACAAATGAGAGCAATTTGTTCTCCCACAAGGCATCAGGTAAACAC - 1 9 6 9
GRE
- 1 9 6 8  AGGCATGAGAATCCATGACCTCGTTGGAATTTCAGGGACTGTTTTTTTCC - 1 9 1 9
LYF-1
- 1 9 1 8  CAGAGGGTCATTTCTCCCTGTTCCAGGCATTGAGGCCAGTAACTATTAAG - 1 8 6 9
NKx2.5
- 1 8 6 8  A T T T C A T C T ^T T ^T T T ^T T T tT T T T T T T T i^A G A C G G G G T C T T G C Ïi - 1 8 1 9
AÏu
- 1 8 1 8  CTGTCGCCCAGCCTGGGGTGCAGTC - 1 7 6 9
- 1 7 6 8  CCGCCTCCCAGGTTCACGCCATTCTC - 1 7 1 9
Alu
- 1 7 1 8  GGACTACAGGCGCCCGCCGCCACGCCœ - 1 6 6 9
- 1 6 6 8  TAGAGÂTGGGGTTTCACCGTGTTÂœCÀGGATGCT - 1 6 1 9
L................................  SSRE
- 1 6 1 8  TCGTGÂTCCGCCCGCCTCGGCCTCCCAAAGTGCTGGGÂTTÂ - 1 5 6 9
" AÏÜ............... LYF-1
- 1 5 6 8  GCCÂCTGCGCCCGGCCTCÂTCTCATTTCTTTATCTGTGAGAGAAGCCACT - 1 5 1 9
 ...................  GATA-1 GATA-1
- 1 5 1 8  ATCACCCCCTAAGGGGCTTCGGTCACCAGCATTTTGTCTGTGTCCTAAAT - 1 4 6 9
- 1 4 6 8  GCTTCAAGACTTACAGACCTGACTCAATACGCTCAGGTAGAAAAAGGGTG - 1 4 1 9
AP-1
- 1 4 1 8  AAATCAAGAATGGCCAACCACTGGAACACTTTAGCCATTGCTCTGAGAGG - 1 3  69 
NF-1
- 1 3 6 8  TGGGTGGATGGAGTGGGCACTATGCTCCCTCCGACGGGGCTTCACTGCCC - 1 3 1 9
- 1 3 1 8  TGGACAGGGGAGAGACAGGCGGCTCACAGAGCATGTGCTGGGCCAGGGCC - 1 2 6 9
- 1 2 6 8  AGTCCCGCCCCCAGGCAGAGATGGCCAGTAAAATAACCACATAATTCCAG - 1 2 1 9  
SP-l/AP-2
- 1 2 1 8  TGGAGTCGCCCTGGGGAAACCGAGGCACTTCAGTTCCTTTTCATCAAGGA - 1 1 6 9
- 1 1 6 8  ACTGATTAAAGTGTGGTCTATTATCTCTGTAGTGGGGAGTCCCGAAAGAT - 1 1 1 9  
NKx2.5 GATA-1 MZF-l/NFkB
- 1 1 1 8  TCCATTCTTCCTCTTCTTGCCCAATGAGAGGGTCAAGGAAGCTTCCACCA - 1 0 6 9
- 1 0 6 8  CCATCCTGACTGTGGCCACCACATCCTGGTGTGAAGCACCACCAGCTTCC - 1 0 1 9
- 1 0 1 8  TCCACAAGAACTTGAAGGTCACCAGCCAGCTTGAGTCCTCCGAAGGTGCT - 9 6 9
- 9 6 8  GTGGCTCAACCAGCAGCCCGTGTAGCAGAGAGCACAAGACCTGGGACTCG - 9 1 9
- 9 1 8  AACTCAGTCCCACCTTCAAGAGGGATCTCCACCACTTTCTGAGCCTCAGT - 8 6 9
- 8 6 8  TTTCACATCTTTGGTTAGGGGCAGGTGGGAAGTTGCCATATTTACCTTGT - 8 1 9
- 8 1 8  TGGGCTCTTTGGAAAAATTAAATGAAATGTTAATGTATGTTACACAACGG - 7 6 9
OCT-1
- 7 6 8  GCTCATAGGAGGGATTCAAAAGCTGTTAGTTCTTTTTCTCCTTTTCCTGG - 7 1 9
STAT
- 7 1 8  AAACGGTATTAAAGAGT - 7 0 2
Figure 3-a. Sequence of the distal region of the human aggrecan 
promoter, -702 to -2368 nucleotides. The proximal 701 bp promoter and 
5’UTR of the human aggrecan gene has previously been sequenced and analyzed for 
promoter motifs and transcription factor binding sites (Valhmu et ah, 1998a). In order 
to further investigate the regulatory regions of the aggrecan gene a DNA fragment 
containing the upstream promoter region was cloned into a luciferase construct that 
contained the proximal 701 bp promoter and 5’UTR. The upstream promoter region 
was sequenced in both directions and was found to contain an additional 1667 bp of 
sequence. The sequence was then analysed for potentially conserved regions and 
putative transcription factor binding sites. Putative transcription factor binding sites are 
underlined or shaded, and an A/w-like sequence is denotedby a dashed box.
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3.2. Sequence homology with known genomic sequences
Identification of potentially conserved sequences in the distal portion of the 
aggrecan promoter was performed with nucleotide sequence databases using the 
BLASTn programme (Altschul et al., 1997) at the National Center for Biotechnology 
Information (NCBI) website.
The BLASTn programme parameters were adjusted so that only alignments 
with high significance values were reported (see Methods Chapter). A total of 1767 
significant alignments were found for the 1667 bp upstream aggrecan promoter 
sequence. The genomic sequences that gave the 10 highest alignment scores are listed 
in table 8. All of the alignments corresponded to a 305 bp region of the promoter 
spanning -1858 to -1550, and each alignment was found at multiple sites within each 
match. To confirm the presence of a highly repetitive sequence, the 305 bp segment 
was scanned through a database containing a select subset of 325 Alu repeats, again 
using the BLAST server. Over 200 significant alignments were reported for the 
sequence. The most significant matches aligned to the Alu-S subfamily of Alu 
sequences.
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Genomic sequence Region of 
hom ology
Alignment
Score*
Significance 
(E) Value*
Human BAG clone from chromosome 
7q21.
-1856 to 
-1552
488 e-135
Human beta T cell receptor locus 
containing dopamine hydroxylase-like 
sequence.
-1857 to 
-1550
478 e-132
Homosapiens chromosome 21q22.3. -1857 to 
-1552
474 e-131
Human DNA sequence from 
chromosome 6q26-27 (clone 125N).
-1857 to 
-1552
466 e-129
Homosapiens chromosome 17 (clone 
hRPK.628).
-1857 to 
-1552
464 e-128
Homosapiens chromosome 16 (BAG 
clone).
-1857 to 
-1552
464 e-128
Homosapiens chromosome 5 (PI clone 
207 c2).
-1857 to 
-1553
462 e-128
Homosapiens chromosome 7pl5-p21 
(BAG clone).
-1858 to 
-1553
460 e-127
Homosapiens chromsome 7p21 (BAG 
clone).
-1851 to 
-1552
458 e-126
Homosapiens chromosome Xq28 
(cosmid).
-1850 to 
-1553
458 e-126
Table 8. Sequence homology of the distal portion of the aggrecan 
promoter. The search was performed using the BLAST programme and genomic 
sequences compiled at the NCBI launcher site. * Score and E value denote a statistical 
evaluation to the alignment as described by the BLAST programme. The E or expect 
value is the number of matches expected with the particular database purely by chance.
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Six alignments were reported outside the Alu repeat region with much lower 
significance values. These alignments were less than 30 bp in length and did not reveal 
any notable homologies with structurally related or tissue-specific genes. Similarly, 
scanning a eukaryotic promoter database produced only six alignments with high 
significance values, which were all located within the Alu repeat region. The two 
highest scoring matches were with the human snRNP gene (small nuclear ribonuclear 
protein) and the human opsin green gene, and spanned the 300 bp Alu repeat region. 
These results indicate that similar Alu sequences are located within the regulatory 
regions of other genes, but their functional significance remains to be determined.
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3.3. Identification of putative transcription factor binding regions
Identification of potential transcription factor binding motifs was performed 
using the Matlnspector programme. The programme uses a library of consensus 
sequences (Matlnd) compiled from nucleotide distribution matrices which contain 
longer nucleotide patterns compared to other sequence analysis programmes (Quandt et 
al., 1995). Well conserved nucleotide patterns were selected for the search by setting a 
core similarity value of 0.9, and only sequence matches that gave high scores with the 
consensus were reported (matrix similarity 0.9).
The upstream promoter region was found to contain binding sites for 
transcription factors that modulate promoter activity in response to growth factors and
cytokines. These include AP-1, NF-kB and STAT binding sites, which show strong
homology to consensus sequences (fig. 3-a, table 9). The distal region also contains 
SP-l/AP-2 and SSRE motifs which are found in the proximal promoter and 5’UTR of 
the human aggrecan gene at multiple sites, and may have an important role in 
regulating promoter activity. In addition the Matlnspector programme identified AP-2 
and GRE motifs which have been shown to act as cis-acting elements in chondrocytes 
(Xie et al., 1998; Rhodes and Yamada, 1995). However, binding sites were also 
identified for factors that show cell-specific or developmental expression in non­
chondrocyte cell lineages including LYF-1, MZF-1 and Nkx-2.5 (table 9). These 
factors showed high scores, suggesting that they may also be involved in the 
regulation of aggrecan promoter activity in chondrocytes.
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Table 9. Putative transcription factor binding sites in the distal region o f  
the aggrecan promoter. The matrix score assigns a quality rating to the match with 
the consensus sequence using the Matinspector programme and Matlnd library of 
consensus patterns (Quandt et ah, 1995). A matrix similarity of 1 occurs if the 
candidate sequence corresponds to the most conserved nucleotide at each position of 
the consensus sequence.
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Poly t (23) AP_1 ^  OTÜ SP-l
NF-kE ^ F2 
AP' 2 SP-l
\  I I N
—  —  —_________________11----1----Exon 1 (5'UTR)
-2368 -1858 -1449 -1135 -701. -580 Ô00 I-------------------
t  J \  J \ \ \
1    SSRE -----
SSRE STAT TFII-I SSREs
Figure 3-b. Sequence motifs and putative transcription factor binding sites of 
the 2.4 kb human aggrecan promoter and exon 1. The upstream region of the 
aggrecan gene contains several putative transcription factor binding sites that may 
confer basal and regulated expression. The transcription initiation (H ) site was 
previously determined by PCR-based cDNA cloning (Valhmu et ah, 1995b). 
Overlapping SP-l/AP-2 sites and a TF II-I motif are located proximal to the TI site 
and may direct assembly of the transcription initiation complex.The promoter and 
exon 1 also contain multiple shear stress response elements (SSREys) (Resnick et 
al., 1993) which are potential sites for mechanical regulation of the aggrecan gene.
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3.4. Summary
Sequence analysis of the distal region of the human aggrecan promoter 
identified several putative regulatory elements that may be involved in the regulation of 
aggrecan gene expression, and provided information that can be used to guide deletion 
analysis and functional studies.
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Chapter 4: BASAL ACTIVITY OF AGGRECAN PROMOTER 
CONSTRUCTS
4.1. Characterization of the proximal 701 bp region of the human 
aggrecan promoter
A DNA fragment containing 0.7 kb of the proximal region of the human 
aggrecan promoter was isolated and cloned into a luciferase reporter construct 
containing the 5’UTR (exon 1 of the aggrecan gene). This promoter-5’UTR construct, 
named pAGCl (-701)75’UTR, was transiently transfected in chondrocytes, and found 
to increase the level of expression 89-fold compared to a promoter-less luciferase 
vector, indicating that this region of the aggrecan gene operates as a functional 
promoter (data not shown).
Unidirectional deletions of the promoter in pAGC1 (-701 )/5 ’ UTR were 
performed using endogenous restriction enzyme sites. Promoter activity was 
determined for each deletion construct after transient transfection in chondrocytes 
maintained in the presence of serum. Deletion to -451 nucleotides caused a 47% 
increase in luciferase activity compared to pAGC 1 (-701 )/5’UTR (p<0.05, fig. 4-a) but 
a further deletion to -179 nucleotides restored activity to the same level as pAGCl(- 
701)75’UTR (p>0.1). This data suggests that the promoter region between -701 and - 
179 contains positive and negative elements that have a moderate effect on promoter 
activity. Removal of all but 52 bp of the aggrecan promoter reduces luciferase activity 
by only 20% (p<0.05), indicating that basal promoter activity is mediated mostly by 
elements located downstream of -52 nucleotides and/or in the 5’UTR.
In contrast to proximal promoter deletions, 5’UTR deletions had a major effect 
on promoter activity. Removal of most of the 5’UTR from the proximal promoter 
construct, to generate pAGCl(-7017+25), caused a 7-fold reduction in luciferase 
activity (p<0.05 fig. 4-b). Similarly, removal of the 5’UTR from the -52 deletion 
construct reduced luciferase expression to background levels. These results
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demonstrate that sequences within the 5’UTR (downstream of +25) are essential for 
proximal promoter activity.
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-701-------------
pAGC 1 (-701 )/5'UTR
-451-------
pAGCl(-451)/5'UTR
-179
pAGC 1 (-179)/5'UTR
-52 -
pAGCl (-52)/5'UTR
Luciferase Activity 
(units LUC/units (3-gal) 
0 1 2 3 4 5 6 7 8 9
i i i i i i i i i
LUC
LUC
> 1
>
LUC >
LUC >
b
(n=12)
(mean ± SD) 
5.0 ±0.5
h *7.3 ±0.8
5.3 ±0.5
4.0 ± 0.4
Figure 4-a. Deletional analysis of the proximal region of the human aggrecan 
promoter. A deletion series was made by digesting pAGC 1 (-701 )/5'UTR with 
endogenous restriction enzymes leaving 5' promoter deletions at the indicated 
positions. Bovine monolayer chondrocytes were transfected with the constructs
and luciferase and (3-gal activities were determined from known standards.
Statistical analysis was performed by oneway ANOVA, and SNK testing 
identifiedsignificantly different groups; * = p<0.05 compared to all other 
constructs.
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Luciferase Activity 
(units Luc/units (3-gal)
0 1 2 3 4 5 6 7
-701----------------_
pAGC 1 (-701 )/5'UTR
LUC *5.9 ± 0.4
+26
-701---------
pAGCl(-701/+26)
LUC
0.8 ± 0.2
+26
-52- LUC 0.1 ±0.3H
pAGCl (-527+26)
Figure 4-b. Promoter activity of 5'UTR-deleted constructs. A 3' deletion was 
made from the -701 and -52 proximal promoter constructs using an endogenous 
B-srBIsite leaving only 26 bp of the 5'UTR. Statistical analysis was performed by 
oneway ANOVA; * = p<0.05.
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4.2. Characterization of an extensive 2.4 kb region of the aggrecan 
promoter
Reporter constructs were made to determine the activity of a larger DNA 
fragment containing 2.4 kb of the aggrecan promoter, in the presence and absence of 
the 5’ UTR. The constructs pAGCl(-2368)/5’UTR and pAGCl(-2368/+25) were 
transiently transfected in chondrocytes and NIH3T3 fibroblasts. Activity of pAGCl(- 
2368)/5’UTR was significantly higher than pAGC 1 (-2368/4-25), by 7-fold in 
chondrocytes and 5.6-fold in NIH 3T3 fibroblasts (fig. 4-c). This is consistent with 
the effect of the 5'UTR in the context of the 701 proximal promoter (presented in fig. 
4-b) and confirms its importance in regulating basal activity in chondrocytes. The 
similar relative activity of pAGCl(-2368)/5’UTR in NIH 3T3 fibroblasts suggests that 
the 5’UTR operates independently of cell type.
87
Relative Luciferase Activity
-2368
-2368
Figure 4-c. Activity of 2368 bp promoter constructs. The constructs were 
transfected in equimolar amounts and maintained for 48 hps in the presence of 10% 
serum. Promoter activity was expressed relative to pAGCl(-2368/+26) for both 
cell types. Statistical analysis was performed by independent t-test; * = p<0.05
compared to pAGC1 (-2368/+26).
+1 ? 2 6
LUC
pAGC 1 (-236B/+26)
>
+1 +375
LUC
pAGCl(-2368)/5'UTR
NIH 3T3
Chondrocytes Fibroblasts
(n=16) (n=7)
1.0 ±0.3 1.0 ±0.7
*7.1 ±3.4 *5.6 ±2.5
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In order to more closely identify regions that regulate promoter activity under 
basal conditions, undirectional deletions were made in pAGCl(-2368)/5’UTR again 
using endogenous restriction enzymes. The constructs were transfected in 
chondrocytes, and the activity of each deletion construct was expressed relative to 
p AGC 1 (-701 )/5 ’ UTR.
Promoter clones with deletion endpoints at, -2368, -1778, -1508, -1079, and - 
780 were significantly more active than pAGCl(-701)/5’UTR construct (p<0.05, fig.
4-d). The -780 nucleotide deletion construct was almost 2-fold more active than the - 
701 construct, suggesting the presence of positively acting cis element(s) within this 
77 nucleotide region. In contrast, a loss of activity was observed with the -1941 
deletion construct, pAGCl(-1941)/5’UTR by 1.5 to 2.1-fold, p<0.05, compared to all 
other constructs except pAGCl(-701)/5’UTR. The deletion profile suggests that a 
negative element exists between -1941 and -1778 but its influence is masked by the 
presence of the upstream region between -2368 and -1941.
To determine if cis-acting elements contained within the upstream promoter 
region function in a cell-specific manner, some of the deletion constructs were 
transfected in chondrocytes and fibroblasts and their activity compared. Promoter 
activity in COS cell fibroblasts was determined relative to chondrocyte activity for each 
deletion construct. Promoter activity was increased 1.6 to 1.8-fold for the -2368 and - 
1941 deletion constructs in fibroblasts compared to chondrocytes (p<0.05, fig. 4-e). 
Activity of the other constructs was not significantly different between the two cell 
types. The enhanced activity of the -2368 and -1941 deletion constructs in fibroblasts 
suggests that the negative element at -1941 (identified in fig. 4-d) is chondrocyte- 
specific.
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-2368--------------------------------- > 1 m c^>
pAGCl(-2368)/5'UTR
-1941--------------------------- 1  11 me
pAGC 1 (-1941 )/5'UTR
-1778-------------------------1:..:. l.,UJC-^ >
pAGCl(-1778)/5'UTR
-1508--------------------- [ 1 me ^
pAGC 1 (-1508)/5'UTR
-1079---------------1 I me
pAGC1 (-1079/5'UTR
-780-----------LU  Luc_2>
pAGCl(-780)/5'UTR
-701-------- h i.:..1 luc
pAGC 1 (-701 )/5'UTR
Relative luciferase activity 
(construct/pAGCl (-701)/5'UTR)
0.5 1.0 1.5 2.0 2.5
mean ± SD
* 1.4 ±0.5
0.9 ± 0.2
* 1.3 ±0.3 
i * 1.7 ±0.4
* 1.6 ±0.3
* 1.9 ±0.2 
1.0 ±0.3
(n=9)
Figure 4-d. Deletional analysis of the distal region of the human aggrecan 
promoter. The deletion series was made using pAGCl(-2368)/5'UTR as a 
template. The constructs were transfected in chondrocytes in equimolar amounts 
and maintained in the presence of 10% serum. The normalized luciferase activity 
was determined for each construct and expressed relative to pAGC 1 (-701 )/5'UTR. 
Statistical analysis was performed by oneway ANOVA and SNK testing identified 
significantly different groups. * = p<0.05 compared to pAGCl(-701)/5'UTR and 
p AGC 1 (-1941 )/5 'UTR.
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Relative Luciferase Activity
Chondrocytes
(n=5)
VOS
fibroblasts
(n=5)
2368-------------------------------------------1 1 LUC 1.0 ±0.3 *1.61± 0.4
-1941 ------1 1 LUC 1.0 ±0.2 * 1.8 ±0.6
-1778 ------1 1 LUC 1.0 ±0.4 2.4 ± 1.5
-1508 ------1 1 LUC 1.0 ±0.4 0.8 ± 0.6
-1079------------ ------ 1 1 LUC 1.0 ± 0.6 0.7 ± 0.7
Figure 4-e. Activity of deletion constructs in COS fibroblasts and 
chondrocytes. The deletion constructs were transfected in both cell types under 
the same experimental conditions. The relative promoter activity between 
constructs in chondrocytes was the same as reported in fig. 4-d. In this experiment, 
promoter activity in COS cells was determined relative to chondrocyte activity for 
each deletion construct. Statistical analysis was performed by independent t-test; 
*p<0.05 compared to chondrocyte activity.
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Relative Luciferase Activity 
(luc cpm/p-gal cpm *1000)
0 20 40 60 80 100 120 140 160 180
YA luc^>
pTKluc+
 ^ T l ü c >
-670 ^
p AGC1 (-2368/-670)TK
-2368
p<0.05, n=5
aggrecan promoter sequence
y?  thymidine kinase promoter
Figure 4-f. Activity of heterologous promoter constructs in chondrocytes. A
thymidine kinase (TK) promoter construct, pTKluc+, was prepared by substituting 
the TK promoter from pRLTK (Promega), for the aggrecan promoter in a 
luciferase reporter plasmid. The 1.7 kb aggrecan upstream promoter region was 
then cloned into pTKluc+ to generate pAGCl(-2368/-701)/TK. The constructs 
were transfected in chondrocytes in equimolar amounts in the presence of 10% 
serum. Statistical analysis was performed by independent t-test.
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In order to further characterize regulatory elements contained within the distal 
region of the aggrecan gene the -2368 to -701 portion of the aggrecan promoter was 
cloned next to a heterologous thymidine kinase (TK) promoter. The construct was 
transfected into chondrocytes and its activity was compared to a construct containing a 
TK promoter only. The presence of the aggrecan distal promoter region reduced TK 
activity by 1.5-fold (p<0.05, fig. 4-f). This result shows that the distal region of the 
aggrecan gene has the ability to modulate activity of promoters, other than aggrecan. 
Furthermore, the negative element(s) contained within the distal region of the aggrecan 
promoter can over-ride the positive elements, when placed next to this heterologous 
promoter.
4.3. Summary
Previous studies demonstrated that the 5’UTR of the human aggrecan gene 
modulates activity of luciferase reporter constructs driven by a CMV promoter 
(Valhmu et al., 1995a, 1998a). The deletion analysis of the human aggrecan promoter 
and 5’UTR performed in the current studies showed that the 5’UTR is essential for 
mediating aggrecan basal promoter activity irrespective of promoter length, and is 
therefore an important regulatory component of the aggrecan gene. However, the 
promoter itself contains cis-acting regions that significantly modulate promoter activity 
under basal conditions. As aggrecan gene expression in chondrocytes is known to be 
modulated by external factors including growth factors and cytokines, it is likely that 
these regions are involved in modulating promoter activity in response to these factors.
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Chapter 5: AGGRECAN PROMOTER ACTIVITY IN RESPONSE TO 
EXTERNAL FACTORS
Deletional analysis of the upstream region of the human aggrecan gene has 
identified positive and negative cis-acting regions that may regulate aggrecan gene 
transcription in chondrocytes. However, chondrocytes are known to modulate 
aggrecan biosynthesis in response to external factors including soluble mediators and 
mechanical forces, but the molecular pathways they activate are not well understood. 
Studies were performed to determine if some specific soluble mediators and 
mechanical factors modulate aggrecan promoter activity, and deletion constructs were 
then used to identify responsive sequences within the 2.4 kb promoter and 5’UTR.
5.1. Promoter activity in the presence of soluble mediators
5.1.1. Effect of IL-1
Interleukin-1 (IL-1) is a cytokine involved in the degradative events in articular 
cartilage. Previous studies by our group and others have shown that IL-1 down- 
regulates both proteoglycan synthesis (Tyler, 1985) and aggrecan steady-state mRNA 
levels, in a dose-dependent manner (Ratcliffe et al., 1996). To determine the effect of 
EL-1 on promoter activity, chondrocytes were transfected with aggrecan promoter 
constructs containing the luciferase reporter gene and were incubated with or without
IL-1 a  (100 units/ml) for 24 hours in the presence of 0.1% BSA. Luciferase activity
was calculated as % activity relative to the untreated controls for each construct. IL-1 
reduced promoter activity for all of the deletion constructs by 60 to 85 % (p<0.05, fig.
5-a). The construct without the 5’UTR, pAGC 1 (-701/+25), was 2 fold more active 
(p<0.05) than the other constructs, although it still had only 34% of the activity of the 
construct in cells not cultured with EL-1. This result shows that the 5’ flanking region 
of the aggrecan gene contains elements that modulate promoter activity in the presence
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of IL-1. The deletion profile suggests that these element(s) are located downstream o f- 
1079 nucleotides in the aggrecan gene.
95
-2368
-1508
-1079
% Luciferase Activity 
(untreated construct = 100%)
0 20 40 60 80 100
- i — i— '— i— '— i—
* 13.2 ± 5 . 2
* 16.7 ±4.0
* 21.7 ± 11.2
* 15.2 ±3.1
* * 34.4 ±8.5
n=5
_ i I i
Figure 5-a. Activity of aggrecan promoter deletion constructs in the presence
of IL-1. Transfected chondrocytes were incubated with or without 100 U/ml IL-1 
for 24 hrs in growth medium containing 0.1% BSA. The luciferase activity of 
untreated constructs was normalized to 100% and the values represent the % 
promoter activity in the presence of EL-1. * = p<0.05 compared to untreated 
controls as determined by independent t-test. ** = p<0.05 compared to IL-1- 
treated groups, as determined by oneway ANOVA and SNK testing.
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In further experiments, IL-1 did not consistently suppress aggrecan promoter 
activity. Therefore it was not possible to pinpoint the specific sequences that confer 
responsiveness to IL-1. The different sensitivities to EL-1 between experiments may be 
due to variabilities within the tissue source (4-6 month calves) as fresh cells were used 
each time, however this discrepency requires further investigation.
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5.1.2. Effect of TNFa
Tumor necrosis factor alpha (TNFa) is another catabolic cytokine that has
similar effects to IL-1 on articular cartilage metabolism. To determine its effect on
aggrecan promoter activity, TNFa was added to transfected chondrocyte cultures at
1200 ng (900 U)/ml for 24 hrs in the presence of 0.1% BSA. The activity of all of the
promoter constructs were suppressed 25 to 55% by TNFa (p<0.05, fig. 5-b). TNFa
also reduced activity of pAGCl(-1778)/5’UTR, pAGCl(-1508)/5’UTR and pAGCl(- 
1079)/5’UTR 40 to 50% in a previous experiment (data not shown). Therefore the 
aggrecan promoter contains regions that regulate promoter activity in réponse to
TNFa. As with IL-1, TNFa had the lowest effect on a construct without the 5’UTR
[pAGC 1 (-2368)7+25] (fig. 5-b), suggesting that this region contains element(s) that 
partly confer reponsiveness to both cytokines. This is consistent with our previous 
findings that demonstrated IL-1 responsiveness in the human aggrecan 5’UTR when
placed next to a CMV promoter (Valhmu et al., 1996). Other TNFa responsive
regions may be located at multiple sites within the promoter as deletions between 
-2368 and -52 in the presence of the 5’UTR did not identify a region that significantly
changed the TNFa effect.
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-2368
-2368
% Luciferase Activity 
(untreated construct = 100%)
20 40 60 80 100
± 12.8
±28.9
±30.9
±17.9
Figure 5-b. Activity of aggrecan promoter clones in the presence of TNFa.
Transfected chondrocytes were incubated with 12 ng(900 U)/ml TNFa for 24 hrs
in growth medioMcontaining 0.1%BSA. As in the IL-1 experiment, luciferase 
activity for each construct was expressed relative to its untreated control. 
Statistical analysis was performed by independent t-test. * = p<0.05 compared to 
untreated control. Aggrecan constructs with deletions at -1778, -1508, and -1079
showed a similar 40-50% level of activity in the presence of 4 ng/ml TNFa (data 
not shown).
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n=5 (p<0.05)
d U
control + TNFa 
12 ng/ml
Figure 5-c. The effect of TNFa on aggrecan mRNA levels in cultured 
monolayer chondrocytes. Non-transfected bovine monolayer chondrocytes were 
cultured and treated with TNFa in parallel with transfected cultures. Total RNA
was extracted from monlayer chondrocytes after 24 hrs treatment with TNFa.
Aggrecan mRNA was amplified and quantified by the method of quantitative RT- 
PCR (Re et al., 1995). The values were normalized to total RNA to account for 
RNA extraction efficiency between samples. Statistical analysis was performed by 
independent t-test.
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To determine if TNFa also regulates aggrecan steady-state mRNA levels, 
quantitative PCR was performed on RNA extracted from chondrocytes cultured in the 
presence or absence of 12 ng/ml TNFa. Treatment of monolayer cultures with TNFa 
for 24 hrs caused a 35% decrease in aggrecan mRNA (p<0.05, fig. 5-c). This result 
indicates that TNFa, like IL-1, affects aggrecan synthesis by regulation of the 
aggrecan mRNA level.
5.1.3. Effect of growth factors on aggrecan promoter activity
Promoter activity in chondrocytes was also measured in the presence of 
growth factors known to modulate aggrecan synthesis under cell culture conditions.
Both IGF-1 and TGFp had no effect on promoter activity at relatively high
concentrations (10 ng/ml). It is possible that sequences that mediate responsiveness are 
not present in the 2.4 kb region of the promoter, or 5’UTR, alternatively these growth 
factors may not regulate aggrecan synthesis at the transcriptional level.
Serum was found to increase activity of the aggrecan promoter compared to 
cultures maintained in 0.1% BSA. The presence of 10% foetal bovine serum in the 
growth media stimulated activity of pAGC 1 (-2368)/5’UTR over 2-fold (p<0.05, fig. 
5-d). This result is consistent with previous studies that showed that serum increases 
proteoglycan synthesis in cartilage explants (Mcquillan et al., 1986a). Further studies 
are required in order to identify the region(s) in the 2.4 kb promoter and/or 5’UTR of 
the aggrecan gene* that are responsive to serum factors.
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Figure 5-d. The effect of serum on aggrecan promoter activity. Bovine 
monolayer chondrocytes were transfected with pAGCl(-2368)75’UTR in the 
presence of 10% foetal bovine serum (FBS). After 24 hrs transfection, the media 
was changed to either DMEM containing 0.1% BSA or 10% FBS and incubated 
for a further 24 hrs. Luciferase activity in the presence of 0.1% BSA was 
normalized to 1. Statisitical analysis was performed by independent t-test.
102
5.2. Promoter activity in response to mechanical/physico-chemical 
stim uli
5.2.1. Effect of changes in extracellular osmolality
The cartilage extracellular matrix contains a large number of cations due to the 
high concentration of proteoglycans containing negatively charged sulphate and 
carboxyl groups on the glycosaminoglycan chains. Loading of cartilage causes a 
sequence of events that leads to fluid loss, increased cation concentration and changes 
osmolality. Changes in media osmolality have been shown to modulate chondrocyte 
volume and proteoglycan synthesis rates in cell culture (Urban et al., 1993). The aim 
of this study was to determine if changing growth media osmolality alters aggrecan 
promoter activity.
Solutions of different osmolality were prepared by diluting DMEM with water 
or adding increasing amounts of sucrose (see Methods Chapter). The osmolality of 
each solution was determined relative to standard DMEM (0.36 Osm). Transfected 
chondrocytes were incubated with the different solutions for 24 hours. Luciferase 
activity was expressed relative to the activity determined for 0.36 Osm for each 
construct. Increasing the media osmolality from 0.09 and 0.3 Osm reduced activity of 
pAGCl(-2368)/5’UTR by 40%(fig. 5-e, A). In the absence of the 5’UTR, activity 
was reduced by 160% (p<0.05, fig. 5-e, B). Media concentrations greater than 0.36 
Osm reduced promoter activity of pAGC1 (-2368)75’UTR by 60 to 70% (p<0.05, fig.
5-e, A), but had no effect in the absence of the 5’UTR (p>0.1, fig. 5-e, B). The 
decrease in aggrecan promoter activity with increasing osmolality corresponds to the 
fall in proteoglycan synthesis rates observed in cultured chondrocytes and cartilage 
explants exposed to hyper-osmotic media, reported by Urban et al. (1993). The results 
from our study indicate that the 2.4 kb promoter and 5’UTR contain elements that 
down-regulate promoter activity in response to osmolality, but regulation at higher 
osmolality requires the presence of the 5’UTR.
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Figure 5-e. The effect of changes in medium osmolality on promoter activity of 
A  pAGCl(-2368)/5’UTR and B  pAGCl(-2368/+25). Solutions of different 
osmolality were prepared by diluting DMEM with water or adding sucrose, and 
added to transfected chondrocytes for 24 h#. Promoter activity for both pAGCl(- 
2368)75’UTR and pAGCl(-23687+25) was calculated and expressed as a 
percentage relative to 0.36 Osm (DMEM only). Statistical analysis was performed 
by oneway ANOVA and SNK testing identified significantly different groups. * = 
p<0.05 compared to 0.36 Osm.
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To investigate the effect of osmolality on cell size, the cell diameter of cultured 
chondrocytes exposed to hypo- (0.18 Osm) and hyper-osmotic (0.58 Osm) media was 
measured over a period of 24 hrs (fig. 5-f). The average chondrocyte cell diameter 
increased by 30% in response to hypay-osmotic shock, but the cells returned to their 
original size within 5 hours and continued to decrease in size after 24 hrs exposure. In 
contrast, chondrocyte cell diameter decreased 15% in the presence of hyper-osmotic 
media and the cells did not return to their original size. These findings suggest that 
osmotic shock induces short term and long term changes in chondrocyte cell volume. 
Similar short-term changes in cell volume have been reported with cultured 
chondrocytes exposed to hyper- and hypo-osmotic media (Urban et al., 1994). It is 
likely that osmotic-regulation of aggrecan gene expression via the promoter is mediated 
through these regulatory changes in cell volume.
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Figure 5-f. The effect of medium osmolality on chondrocyte cell s ize .
Bovine monolayer chondrocytes were isolated and cultured in standard DMEM (0.36 
Osm) for 24 hrs. The cells were then incubated with either 0.18 Osm or 0.58 Osm 
media and recorded using an epifluoresence microscopy system. Hoffman modulation 
contrast images of chondrocytes subjected to osmotic shock were obtained at regular 
time intervals for up to 24 hours. The images presented in the figure were recorded 
after 6 minutes of osmotic shock. Cell size was quantified by measuring cell diameter 
using MetaMorph software and a lOx objective. The values were expressed as a 
percentage of the initial cell diameter and each data point represents the mean of 6-8 
cells.
5.2.2. Effect of fluid flow-induced shear stress
Chondrocyte biosynthetic activity is also known to be modulated by 
mechanical signals as well as growth factors and cytokines. As elucidation of these 
signals is complex, in vitro cell culture models have been developed in order to 
understand how chondrocytes respond to specific physical stimuli. One such model 
was developed within our group to generate mechanical shear stress in cultured 
chondrocytes using fluid flow (Hung et al., 1995). This experimental system was 
used to investigate the role of shear-stress in the regulation of aggrecan promoter 
activity.
Transfected chondrocytes were cultured for 2 hours in the presence of fluid 
flow at 16 dynes/cm2 and the activity of pAGC 1 (-2368)/5’ UTR was determined. 
Exposure to fluid flow induced shear stress reduced aggrecan promoter activity by 
almost 50% (p<0.05, fig. 5-g). The results indicate that the 2.4 kb promoter and/or 
5’UTR contains region(s) that modulate promoter activity in response to mechanical 
shear. This study also provides preliminary evidence to suggest that aggrecan gene 
expression may be regulated by chondrocytes in response to shear stress.
107
5'UTR
pAGCl(-2368)/5'UTR
I I no flow
16 dynes/cm^.
(n=6, p< 0.05)
Figure 5-g. Effect of flow-induced shear stress on aggrecan promoter activity.
Transfected chondrocytes were cultured in silicone wells and subjected to 2 hr 
fluid flow in the presence of standard growth media, 46 hours after transfection. 
The cells were harvested immediately afterwards. Statisitical analysis was 
performed by independent t-test.
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5.3. Summary
car*
These studies have demonstrated that cytokines IL-1 and TNFoeAact to down-
regulate aggrecan gene expression via the promoter. Deletion analysis identified the 
5’UTR as well as the regions in the promoter, to modulate activity in the presence of 
these cytokines. The presence of multiple cytokine-responsive elements suggests that 
complex molecular pathways are involved in cytokine regulation of aggrecan gene 
expression. Regions in the 2.4 kb promoter and 5’UTR were also found to be 
responsive to changes in extracellular osmolality and mechanical shear stress. 
Therefore a variety of extracellular stimuli are capable of regulating activity of the 
human aggrecan promoter. Deletion construct analysis can be used to identify the 
intracellular signalling pathways that may be activated by these stimuli, in order to 
further understand the molecular mechanisms by which chondrocytes regulate 
aggrecan gene expression.
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Chapter 6: THE ROLE OF MEK-1 IN THE REGULATION OF 
AGGRECAN GENE EXPRESSION.
The object of this study was to identify the intracellular molecular mechanisms 
by which chondrocytes regulate aggrecan gene expression in response to 
environmental stimuli. The first family of signalling molecules studied was the 
mitogen activated protein kinases (MAPKs). The MAPKs have been found to be 
activated by fluid shear stress in endothelial cells (Tseng et ah, 1995) and also
modulate proteoglycan synthesis in response to IL-1 and TNFcc (Pratta et ah, 1998).
As we have previously shown that the aggrecan upstream region contains regulatory 
elements that modulate promoter activity in response to these external factors, it is 
likely that MAPKs are involved in regulating aggrecan synthesis at the promoter level.
6.1. Effect of MEK-1 inhibition in regulating aggrecan gene expression
The effect of MEK-1/ERK-1/2 was investigated by treating chondrocyte 
cultures with PD98059 (CalBiotech). PD98059 is a highly specific pharmacological 
inhibitor of MEK-1 which prevents activation of downstream ERK-1/2 by MEK. In 
order to study the effect of MEK-1 on aggrecan gene expression, aggrecan steady state 
mRNA levels were measured in chondrocyte cultures after a 24 hour incubation with
25pM PD98059.
Incubation with PD98059 was found to increase aggrecan steady state mRNA 
levels 4-fold compared to untreated control cultures (p<0.05, fig. 6-a). This result 
indicates that the MEK-1 pathway has an inhibitory effect on aggrecan gene expression 
in chondrocytes.
In order to determine if MEK-1 regulates aggrecan gene expression at the 
transcriptional level, the activity of the largest promoter clone, pAGCl(-2368)/5’UTR 
was measured in the presence and absence of PD98059. Promoter activity of pAGCl(- 
2368)/5’UTR increased in the presence of PD98059 in a dose-dependent manner (fig.
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6-b|h At concentrations of IjxM or higher, promoter activity was significantly
increased above untreated cultures (p<0.05). At 5pM and 25jiM promoter activity was
highest, being 3-fold greater than the untreated cultures. The results indicate that the
aggrecan promoter and/or 5’UTR contains elements that are regulated by the MEK-
1/ERK-1/2 pathway.
The phosphorylation status of ERK-1 and ERK-2 (p42 and p44 MAPK) was
Cfi‘3 6-k ll)
also measured in the transfected chondrocytes treated with PD98059A MAPK levels 
were detected by Western analysis using the PhosphoPlus p44/42 MAP Kinase 
Antibody kit - and their levels were quantified by digital analysis. ERK-1/2
phosphorylation was suppressed at concentrations of 200nM and 25pM PD98059
(p<0.05), but unlike promoter activity, the effect did not appear to be dose-dependent^^ 
It is possible that a low signal made it difficult to detect more than 2-fold reductions in 
phosphorylation, as many of the bands appeared close to background.
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Figure 6-a. The effect of PD98059 on aggrecan mRNA levels in cultured 
monolayer chondrocytes. Non-transfected bovine monolayer chondrocytes were 
cultured and treated in parallel with transfected cultures. Total RNA was extracted 
from chondrocytes after 24 hrs treatment with PD98059. The mRNA copy number 
was calculated by PCR of experimental samples and aggrecan standards of known 
concentration. To account for inter-assay variability, the values were normalized to 
total RNA. PCR products were quantified by computer image analysis of agarose 
gels. The p-value was determined by independent t-test.
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Figure 6-b ii. Effect of PD98059 on ERK-1/2 MAPK phosporylation levels in 
primary bovine monolayer chondrocytes. Protein samples from transfected 
chondrocytes were electrophoresed and transfered to nitrocellulose. ERK-1/2 levels 
were detected using the Phototope-HRP Western Blot Detection Kit and the bands
were quantified by digital analysis. The values were normalized to the p-galactosidase
activity in each transfected sample. *p<0.05 denotes significance compared to control 
group (0).
*p<0.05
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Figure 6-bi. Promoter activity of pAGCl(-2368)/5’UTR in the presence of
PD98059. Chondrocytes were treated with different concentrations of PD98059, 
24 hrs after transfection with pAGC 1 (-2368)/5’ UTR and incubated for a further 24 
h#. Aggrecan promoter activity was determined from cell extracts, and expressed
as units of luciferase activity normalized by P-galactosidase.
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6 .2 .  Activity of promoter deletion constructs in the presence o f  
PD 98059
Deletion constructs were used to identify regulatory elements of the human 
aggrecan gene responsive to the effect of PD98059. As PD98059 concentrations above
5|iM had a maximal effect on promoter activity, 25jiM was used for subsequent 
promoter studies (unless otherwise stated).
6.2.1. Effect of promoter deletions
The promoter constructs tested initially had deletion endpoints at -2368, -1508, 
-780 and -52, and contained the 5’UTR. The activity for each construct was 
normalized to its activity in untreated cultures (fig. 6-c). Each promoter construct was 
3 to 4 times more active in the presence of PD98059 (p<0.05). Sequential promoter 
deletions to -52 nucleotides did not significantly reduce the effect, suggesting that 
elements mediating PD98059 responsiveness are located downstream of -52 or in the 
5’UTR.
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Figure 6-c. Relative activity of sequentially deleted promoter constructs in the 
presence of 25 jjM PD98059. Promoter activity for each construct was expressed
relative to its activity under control conditions (10% FBS). All of the constructs 
contained the full length 5’UTR. Statistical analysis was performed by oneway 
ANOVA, and the p-values are quoted for differences between treated and 
untreated groups for each construct.
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6.2.2. Effect of 5 ’UTR deletions
Promoter constructs containing 5’UTR deletions were made from pAGCl(- 
2368)/5’UTR. The new constructs pAGC 1 (-23687+25) and pAGC 1 (-23687+213) 
were used to determine the effect of 5’UTR deletions on basal activity and the 
PD98059 response.
Under basal conditions removal of most of the 5’UTR (pAGCl(-23687+25)) 
causes almost a six-fold reduction in promoter activity (fig. 6-d, A). This is consistent 
with the activity reported for the same sized construct (Chapter 4; fig. 4-c). 
Regeneration of this clone for this study reconfirms the importance of the 5’UTR in 
regulating basal promoter activity. However removal of only 162 bp from the 
downstream end of the 5’UTR (pAGC 1 (-23687+213)) stimulates promoter activity to a 
level almost 2-fold greater than pAGC1 (-2368)/5’UTR. This suggests the 5’UTR 
contains a negatively acting cis element(s) as well as regions essential for basal 
activity.
Unlike promoter deletions, 5’UTR deletions significantly effect the PD98059 
response. In the presence of PD98059 (fig. 6-d, B), the relative activities of both 
pAGCl (-23687+25) and p AGC 1(-23687+213) were reduced from 4.2 to 1.8-fold, 
compared to pAGCl(-2368)5’UTR (p<0.01). This indicates that the 5’UTR mediates 
responsiveness to PD98059, through element(s) located downstream of position 
+213.
To test whether regions that confer responsiveness to PD98059 are found in 
other promoters, we also determined the response of Thymidine Kinase (TK) and 
Cytameglavirus (CMV) promoter-luciferase constructs in chondrocytes (fig. 6-e). TK 
promoter activity did not change in the presence of PD98059, but CMV promoter 
activity was stimulated 1.8-fold above untreated cultures (p<0.05). A third construct 
was also tested which contained the CMV promoter and the aggrecan 5’UTR, (pHA 
5’UTR). In the presence of PD98059 its activity was stimulated 4-fold compared to 
control cultures and was significantly more active than the CMV promoter alone
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(p<0.01). This data shows that the 5’UTR can confer PD98059 responsiveness to a 
non aggrecan-related promoter.
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Figure 6-d. Activity of 5 UTR (exon 1) deletion constructs. The construct 
containing the 2368 bp promoter and 5' UTR, pAGCl(-2368)/5'UTR, was used as 
a template to generate two 5’UTR deletion constructs, pAGCl(-23687+25) and 
pAGGl(-23687+213) which had 350 and 162 nucleotides removed from the end of 
the 5’UTR respectively. A. Basal activity. The constructs were transfected in 
equimolar amounts in the presence of 10% FBS. Luciferase activity was 
determined for each of the constructs, and expressed relative to pAGCl(- 
23687+25). B. Relative activity in the presence of PD98059. The drug was added 
to transfected cultures and promoter activity was expressed relative to the 
untreated control groups. Statistical analysis was performed by oneway ANOVA 
to determine significance between treatment groups.
0 2 4 6 8 10 12 14
T 1 1 1 1 1 1 1 1 1 1 1 1 1 1
(p<0.05, n=10)
i *
Relative luciferase activity 
(treated/untreated control)
(p<0.01, n=10)
118
TK
CMV
CMV 5'UTR
Relative luciferase activity 
(treated/untreated control)
0 1 2 3 4 5 6
>
(p<0.05, n=10)
m m #
Figure 6-e. Relative activity of heterologous promoters in the presence of 
PD98059. The luciferase reporter constructs were modified to contain a 
thymidine Kinase (TK) and Cytameglavirus (CMV) promoters. These constructs 
is referred to as pTKluc and plucneo. A third construct contained the 5’UTR 
cloned downsteam of the the CMV in plucneo and is known as pH A 5’UTR. The 
constructs were transfected under the same conditions as previously. Statistical 
analysis by oneway ANOVA showed that all treatment groups were significantly 
different from each other (* = p<0.05).
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6.3. Identification of external factors that modulate aggrecan promoter 
activity through the MEK-1 pathway
The previous set of experiments demonstrated that aggrecan gene expression is 
suppressed in chondrocytes by MEK-1 via the 5’UTR (exon 1) of the aggrecan gene. 
The aim of the next part of this study was to identify external factors that modulate 
aggrecan promoter activity through the MEK-l/ERK-1/2 signalling pathway.
6.3.1. Effect of IL-1 on promoter activity in the presence of PD98059
CAA
Results presented in chapter 5 showed that IL-1 Adown-regulate/ aggrecan 
promoter activity, and this may be mediated in part by the 5’UTR. The aim of this 
study was to determine the involvement of MEK-1 in the effects of IL-1 on aggrecan 
promoter activity. To study promoter activity, chondrocytes were transfected with 
pAGCl(-1079)/5’UTR and incubated with increasing levels of IL-1, in the presence 
and absence of the MEK-1 inhibitor, PD98059.
IL-1 suppressed pAGCl(-1079)/5’UTR activity approximately 50% at 0.01, 
0.1, and 10 ng/ml, but had only a minor effect at 1 ng/ml (fig. 6-f; black circles). This 
is consistent with the results that showed IL-1 signficantly reduces activity of the 
human aggrecan promoter, presented in Chapter 5. PD98059 caused a 4-fold increase 
in basal activity, which is also consistent with previous results, but it did not 
significantly change the suppressive effect of IL-1 (fig. 6-f). However, at lower IL-1 
concentrations, the presence of PD98059 increased promoter activity by 20%, 
indicating that it may have partially blocked the effect of IL-1. Conversely, at higher 
IL-1 concentrations PD90859 did not reduce the suppressive effect of IL-1, suggesting 
the involvement of a MEK-1-independent signalling pathway. Further analysis is 
required in order to more precisely define the role of the MEK-l/ERK-1/2, and other 
signalling pathways in regulating aggrecan transcription in response to IL-1.
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Figure 6-f. Effect of PD98059 on IL-1 -mediated suppression of promoter 
activity. Chondrocytes transfected with pAGC 1 (-1079)/5 ’UTR were incubated with 
different concentrations of IL-1 in the presence and absence of PD98059 24 hrs prior 
to harvesting, in DMEM containing 1% FBS. Promoter activity in the presence of IL-1 
was determined and expressed as a percentage of the non-IL-1 treated control for both 
PD-untreated (black circles) and PL-treated (white circles) groups. Statistical analysis 
was performed using independent t-tests. No significant differences were found 
between PD-untreated and PD-treated groups.
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6.3.2. Effect of fluid shear on aggrecan promoter activity in the 
presence of PD98059
As well as growth factors and cytokines, MAPKs are also known to respond 
to physical stimuli. It is possible that MAPKs are involved in modulating aggrecan 
synthesis in response to mechanical loads. In the previous chapter we used a flow 
chamber to demonstrate the effect of mechanical shear on aggrecan promoter activity. 
This system was used again to investigate the role of MAPKs in regulating promoter 
activity in chondrocytes, subjected to fluid flow-induced shear stress.
Transfected chondrocytes were cultured for 2 hours in the presence of fluid 
shear at 16 dynes/cm2 and activity of pAGCl(-2368)/5’UTR was determined. To 
assess whether flow-induced suppression of promoter activity was mediated through 
MEK-1, chondrocytes were incubated with 200 nM PD98059 24 hrs after transfection 
(A 200 nM concentration was used as we found it to inhibit ERK-1/2 phosphorylation 
without significantly altering baseline promoter activity). Fluid flow-induced shear 
stress of chondrocytes significantly reduced aggrecan promoter activity by 40% 
(p<0.05, fig. 6-g, A), consitent with our previous observation in chapter 5. PD98059 
was found to prevent the fluid shear-induced suppression in promoter activity (fig. 6- 
g, B). No significant differences were observed between the no-flow control and 
drug-treated groups. The results suggest that fluid-induced shear stress regulates 
aggrecan promoter activity through the MEK-l/ERK-1/2 pathway. In addition, 
coworkers have found that ERK-1/2 phosphorylation is increased in a time dependent 
manner in chondrocytes, subjected to fluid shear (Valhmu et al., 1998b). These 
findings demonstrate that ERK-1/2 MAPKs are important in transducing mechanical 
signals in chondrocytes.
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Figure 6-g. Effect of flow on aggrecan promoter activity in the presence
of PD98059. Chondrocytes were cultured in silicone wells and transfected with 
pAGCl(-2368)/5’UTR. The cells were subjected to 2 hr flow 46 hrs after transfection 
and harvested immediately afterwards. A. Standard media (DMEM + 10% FBS) . B + 
PD98059. The drug was added at 200 nM 24 hrs prior to flow. Statistical analysis was 
performed by oneway ANOVA and SNK. *p<0.05 vs all other groups.
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6.4. The effect of tyrosine kinase inhibitors on aggrecan promoter 
activity
The object of the next part of the study was to determine if other signalling 
pathways regulate aggrecan promoter activity in chondrocytes. Receptor associated 
tyrosine kinases transmit signals from the cell membrane and are known to activate 
downstream signalling molecules such as MAPKs. To investigate if tyrosine kinases 
are also involved in regulating aggrecan promoter activity, transfected chondrocytes 
were treated with a number of selective tyrosine kinases inhibitors. Table 10 
summarizes the effects of the inhibitors used in the study.
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Inhibitor Effects Amount
used
R ef.
Genistein Broad range tyrosine kinase inhibitor. Inhibits 
EGFR and pp60v"src phosphorylation (IC50=20-25
pM). Also has minor effect on PKC and PKA 
(IC50>150pM).
25 pM Akiyama 
et al., 
1987
Tyrphostin 
B42(AG 490)
Selective inhibitor of JAK-2. 2 pM Meydan 
et al., 
1996
Tyrphostin 
AG 1295
Highly specific inhibitor of PDGFR (IC50= 0.5jiM) 
Inhibits EGF and HER-2 only at IC50> 100 pM
2 pM Levitski
and
Gazit,
1995
Tyrphostin 
AG 1498
Highly specific and potent inhibitor of EGFR (IC50 
> 3 nM).
Inhibits PDGFR and HER 1-2 only at IC50 > 100 
pM).
200 nM Levitski
and
Gazit,
1995
Table 10. Inhibitors used to investigate tyrosine kinase regulation o f  
aggrecan promoter activity. Transfected chondrocytes were incubated with the 
inhibitors at the indicated concentrations (see fig. 6-h).
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Figure 6-h shows the effect of the tyrosine kinase inhibitors on activity of 
pAGC 1 (-2368)/5’UTR and pAGCl(-2368/+25) respectively. The only inhibitor to 
have a significant effect on pAGCl(-2368)/5’UTR was Tyrphostin AG 1478 (Tyr AG 
1478) (fig. 6-h, A), which caused a 50 % reduction at 200 nM (p<0.05). In the 
absence of the 5’UTR (fig. 6-h, B) Tyr AG 1478 still reduced promoter activity 
(p<0.05) suggesting that sequences in the promoter and not the 5’UTR are responsive 
to Tyr AG 1478 inhibition.
All of the tyrosine kinase inhibitors suppressed pAGC 1 (-23687+25) activity 
(fig. 6-h, B). This indicates that tyrosine kinases have a stimulatory effect on promoter 
activity in the absence of the 5’UTR. Genistein, the broad range tyrosine kinase 
inhibitor, had the greatest effect, reducing promoter activity by more than 50%.
The effect of Genistein on aggrecan promoter activity was investigated further 
using another 5’UTR deletion construct, pAGCl(-23687+213). Promoter activity of 
pAGCl(-23687+25) and pAGC 1 (-23687+213) were reduced 60% in the presence of 
Genistein (fig. 6-1). Conversely, no suppression was observed with the full promoter 
construct, pAGC 1 (-2368)75 ’UTR. This observation may be due to the existence of 
elements upstream of position +213 in the 5’UTR, that override regulation by tyrosine 
kinases.
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Figure 6-h. Effect of tyrosine kinase inhibitors on aggrecan prom oter activity.
A  pAGCl(-2368)/5’UTR, B pAGCl(-2368/+25). Chondrocytes were treated with 
the inhibitors 24 hrs after transfection and incubated for a further 24 hrs. The 
inhibitors were added at the indicated concentrations in DMEM containing 10% 
FBS. *p<0.05 vs untreated control.
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Figure 6-i. Relative activity of 5’UTR deletion constructs in the presence of 
Genistein. The 5’UTR deletion constructs from fig.6-d were transfected in the
presence of Genistein (25 pM in DMEM + 10% FBS). The untreated controls for
each construct were normalized to 100%. *p<0.05 denotes significance between 
the drug-treated groups.
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6.5. Summary
These studies have shown that inhibition of MAPK kinase (MEK-1) by 
addition of PD98059 increases aggrecan gene expression in primary chondrocytes. 
Subsequent deletion analysis demonstrated that regulation by the MEK-l/ERK-1/2 
pathway is primarily mediated through a 162 bp sequence located at the downstream 
end of the 5’UTR of the human aggrecan gene.
MEK-1 inhibition also prevented down-regulation of aggrecan promoter 
activity in response to fluid-induced shear stress, but not IL-1. Therefore other 
signalling pathways are likely to be involved in the regulation of aggrecan gene 
expression in response to IL-1. Inhibition of specific tyrosine kinases including JAK- 
2, PDGFR and EGFR by addition of specific and broad-range tyrosine kinase 
inhibitors was also found to regulate aggrecan promoter activity in chondrocytes. In 
contrast to MEK-1, regulation by these inhibitors was found to occur predominantly 
through the 2.4 kb promoter rather than the 5’UTR.
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Chapter 7: DISCUSSION
Aggrecan is an extensively studied proteoglycan that is essential for the normal 
function of articular cartilage, enabling the tissue to withstand high mechanical loads 
throughout life. Alterations in aggrecan structure, or depletion of aggrecan levels in the 
ECM as observed in genetic and degenerative joint diseases can severely compromise 
articular cartilage function. A large number of envronmental stimuli including 
mechanical and biochemical factors have been found to modulate aggrecan synthesis in 
articular cartilage chondrocytes but the intracellular mechanisms that control the 
regulation of aggrecan expression remain poorly understood. Isolation and 
characterization of regulatory regions of the aggrecan gene performed in our studies, 
have demonstrated that transcriptional regulation is a major point in the synthetic 
pathway at which aggrecan synthesis is regulated. Furthermore, deletion analysis and 
transient transfection studies have identified regions in the aggrecan gene that are 
responsive to regulation by intracellular signalling molecules.
7.1. The aggrecan promoter contains an A /m-like sequence
The sequence of the human aggrecan promoter distal region has been obtained. 
The distal promoter region was found to contain minimal homology with known 
genomic and promoter sequences, except for a 300 bp A/w-like region. Alu sequences 
are short transposable DNA sequences that constitute approximately 5% of the human 
genome. They are characterized by a high G+C content and a poly(A)tail. Alu 
sequences are not commonly found in the promoter regions of genes (Britten, 1994), 
though some have been reported to have gene regulatory functions. For example, an
Alu sequence in the IgE FceRI-y chain promoter contains positive and negative cis-
acting elements that operate in a cell-specific manner (Brini, 1993). The lymphoid CDS 
alpha gene is also regulated by an enhancer contained within an Alu sequence, and the 
authors suggest that the Alu sequence has adapted to an enhancer function via selected
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base changes that allow protein binding (Hambor et ah, 1993). The enhancer region of 
this gene contains functionally important GATA and LyF-1 transcription factor binding 
sites that are also contained within the A/w-like region in the human aggrecan 
promoter. Therefore it is possible that the Alu sequence located in the distal region of 
the aggrecan promoter is involved in the regulation of gene expression.
The distal promoter region of the human aggrecan gene showed no sequence 
homology to other aggrecan or cartilage-specific promoters. Low sequence homology 
has already been reported between the chick, mouse and rat aggrecan promoters (Pirok 
et al., 1997), suggesting that large regions of the proposed regulatory regions of the 
aggrecan gene are not conserved across species. However, a promoter motif 
consisting of a TATG repeat, proximal to the transcription start site of the human 
aggrecan gene is conserved in the rat and mouse genes (Valhmu et al., 1998a). This 
homology suggests that the mechanisms controlling transcription initiation of the 
aggrecan gene are not species specific.
The aggrecan promoter was also found to contain a number of binding sites for 
transcription factors that may regulate its expression. The significance of these sites 
will be discussed in the context of the functionally important regions in which they 
were found.
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7.2. The aggrecan gene contains regulatory regions that enhance and 
suppress its expression
Under basal conditions, high level expression of the aggrecan gene was found 
to be critically dependent on sequences present in exon 1 (5’UTR) rather than the 
promoter. This was demonstrated by functional studies that showed; 1) deleting the 
promoter from -701 to -52 reduced luciferase expression only 1.3-fold(fig. 4-a); 2) 
removing the 5’UTR from promoter constructs leaving a 5’ flanking sequence of -701 
to +25 (fig 4-b) or -2368 to +25 (fig. 4-c) reduced luciferase activity 6- to 7-fold. The 
stimulatory effect of the 5’UTR was not chondrocyte-specific, causing over a 5-fold 
induction in promoter activity in NIH 3T3 fibroblasts (fig. 4-c). It is possible that
Corresponding t)
sequences.ia.the 5’UTR to bind to general transcription factors that mediate formation 
of the trancription initiation complex.
The 5’UTR contains clusters of transcription factor binding sites for SP-1 and 
AP-2, which are thought to be involved in transcription initiation of TATA- and 
CAAT- less promoters (Azizkhan et al., 1993). Multiple SP-1 and AP-2 binding 
motifs are also present in the proximal promoter/exon 1 region of the human perlecan 
gene (lozzo et al., 1997). Perlecan is a heparan sulphate proteoglycan that is expressed 
in vascular tissues (lozzo et al., 1994), and developing and adult cartilage (Handler et 
al., 1997; SunderRaj et al., 1995). The perlecan promoter also lacks a TATA motif 
and exhibits similar functional characteristics to aggrecan as unidirectional deletions up 
to -52 (for aggrecan) and -132 (for perlecan) retain the majority of promoter activity, in 
the presence of exon 1. SP-1 sites also modulate type X collagen promoter activity in 
hypertrophic chondrocytes (Long et al., 1998), and basal and cAMP-induced biglycan 
promoter activity in a leiomyosarcoma cell line (Ungerforen et ah, 1998). The 
structural and functional similarités of these genes implies that SP-1 may be important 
for transcription intiation of chondrocyte genes including aggrecan.
Deletion analysis of the 2.4 kb region upstream of the transcription start site 
identified cis-acting regions, which may be important regulatory components of
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aggrecan gene expression. The regions had a moderate effect on promoter activity 
compared to the 5’UTR and were identified by stepwise deletion of the aggrecan 
promoter from -701 to -52 (fig. 4-a) and -2368 to -701 (fig. 4-d). Positive regions 
were identified between -2368 and -1941, and -780 to -701, as these deletions 
significantly decreased luciferase activity. Likewise, deletions between -1941 to - 
1778, and -701 to -451 increased activity, indicating the presence of negative regions. 
Although these regions were not fully investigated, additional studies have shown that 
the negative region between -1941 to -1778 might be an important regulatory 
component of the aggrecan gene. For example it did not have an inhibitory effect in 
COS cell fibroblasts (fig. 4-e), which suggests that it may respond to chondrocyte- 
specific transcription factors. Furthermore the presence of the distal portion of the 
aggrecan promoter, -2368 to -670, which contained the negative region, also down- 
regulated a heterologous promoter (fig. 4-f). The ability of this region to modulate a 
heterologous promoter in the absence of downstream promoter sequences suggests 
that it operates in a position-independent manner and may therefore contain a classical 
silencer.
The negative region between -1941 and -1778 was found to contain the Alu 
repeat region. Alu sequences have been implicated in the negative regulation of 
transcription of the MOK-2 (Arrauz et al., 1994) and parathyroid hormone (PTH) 
genes (McHaffie and Ralston, 1995). It should be noted that complete removal of the 
Alu sequence from the human aggrecan gene by deletion to -1508 generated the most 
active promoter construct (fig. 4-d). This Alu repeat also contained pyrimidine rich 
sequences including a tract of 23 dT residues. The chick aggrecan promoter also 
contains a dT tract but it does not form part of an Alu repeat, and its functional 
significance is unclear. However, pyrimidine rich sequences have been found to 
regulate transcription of genes for the androgen receptor (Chen et al., 1997), matrix- 
metalloprotease-9 (MMP-9) (Himelstein, 1997), and can initiate cell specific 
expression of the alpha (1) procollagen gene in fibroblasts (Dhalla et al., 1998). 
Further functional characterization of this negative cis-acting region in the aggrecan
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promoter is required to substantiate the role of these structural motifs as transcriptional 
suppressors of aggrecan gene expression.
It should be noted that the regulatory regions have been identifiedjout of context 
of the complete gene and may require other elements to be fully operative. This may 
explain why positive and negative-cis acting regions identified in the 2.4 kb promoter 
had only a moderate effect on basal activity compared to the 5’UTR. Other 
components of the aggrecan gene have been implicated in transcriptional regulation. 
Intronic sequences have been found to modulate activity of the rat aggrecan promoter 
(Doege et al., 1994), as well as other cartilage-specific genes including link protein 
(Rhodes et al., 1991) and type II procollagen (Horton et al., 1987; Mukhopadhyay et 
al., 1995). Previous studies by coworkers also demonstrated that the 3' untranslated 
region (3'UTR) regulates aggrecan gene expression by suppressing promoter activity 
in chondrocytes (Valhmu et al., 1998a).
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7.3. Biochemical mediators modulate aggrecan promoter activity
Transient cell transfection studies with deletion constructs also demonstrated 
that sequences in the 2.4 kb promoter and 5’UTR of the human aggrecan gene regulate 
promoter activity in response to a variety external factors including cytokines, 
osmolality, and mechanical stress.
The actions of the inflammatory cytokines, IL-1 and TNFcc in cartilage
degradation have been well characterized. They promote proteoglycan catabolism 
through the activation of proteases (Murphy et al., 1986; Campbell et al., 1988), and 
are powerful inhibitors of aggrecan synthesis (Tyler, 1985; Saklatvala, 1986). Our
transfection studies showed that both EL-1 and TNFa act via the promoter to
downregulate aggrecan gene expression. In addition, we found that TNFa
downregulated aggrecan mRNA levels under the same culture conditions, as 
previously found with IL-1 (Ratcliffe et al., 1996). These findings suggest that
suppression of aggrecan synthesis by IL-1 or TNFa in chondrocytes is primarily
mediated at the transcriptional level. IL-1-mediated transcriptional regulation in 
chondrocytes has also been reported for the type II collagen gene (Col2Al), via 
sequences located between the -577 to +3428 region of the gene (Goldring et al., 
1994).
Deletion analysis identified regions within the 2.4 kb-5’UTR portion of the 
aggrecan gene that modulate activity in response to these cytokines (fig. 5-a, fig. 5-b). 
The promoter activities of all the aggrecan deletion constructs were suppressed by LL-1
and TNFa, but constructs without the 5’UTR were most active, indicating that
cytokine responsive elements are located in this region of the gene. This is consistent 
with previous studies by coworkers that showed the 5’UTR to be necessary for IL-1- 
mediated down-regulation of a CMV promoter (Valhmu et al., 1996). Deletion 
analysis also showed that IL-1 responsiveness was retained within a flanking region of
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-701 to +25 (fig. 5-a), while TNFa responsiveness was retained (but reduced) by a
5’UTR deletion to +25, and a promoter deletion to -52 (fig. 5-b) . Therefore it is 
possible that a region spanning -52 to +25 is predominantly responsible for mediating 
responsiveness to both cytokines as all the deletion constructs contained this region.
The aggrecan promoter and 5’UTR were found to contain motifs for 
transcription factors that have the potential to be regulated by cytokines such as IL-1
and TNFa. Several of these motifs also exist at multiple sites in the promoter and
5’UTR, and include AP-1, AP-2, AP-4 and SP-1. AP-1 is most closely linked to 
cytokine-induced transcriptional regulation and is considered to have a fundamental 
role in the degradative processes of articular cartilage. Expression of matrix 
metalloproteases— necessary for the degradation and remodelling of connective 
tissues, is regulated by cytokines via the activation of AP-1 (Brenner et al., 1989; 
Conca et al., 1989). In chondrocytes, inhibition of AP-1 suppresses IL-1-induced 
activation of collagenase-1 (matrix metalloproteinase-1 ) and stromelysin (matrix 
metalloproteinase-3) (Hui et al., 1998). AP-1 may also have a direct effect on aggrecan 
synthesis, as overexpression of c-fos (a component of the AP-1 heterodimeric 
complex) decreases proteoglycan synthesis in chondrocytes (Tsuji et al., 1996).
AP-1 sites that mediate transcriptional regulation in response to cytokines and 
growth factors have been identified in the promoter region of a number of genes, some
of which are which are expressed in chondrocytes and include a2(l) collagen
(COL1A2) (Chung et al., 1996), collagenase (Jonat et al., 1992), and decorin 
(Mauviel et al., 1996). Five AP-1 sites were found in the aggrecan promoter at -2188, 
-1450, -599, -23 and +107. The sites at -599, -23 and +107 are contained within
regions that retain responsiveness to IL-1 and TNFa. Further functional
characterization of these regions is necessary to determine if either of these putative
AP-1 sites is essential in mediating IL-1 and TNFa-induced downregulation of
aggrecan gene expression.
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Despite their ability to modulate aggrecan expression, the growth factors IGF-1 
and TGF(3 failed to regulate activity of the aggrecan promoter constructs. These
findings suggest that both IGF-1 and TGF-p responsive elements are not contained
within the 2.4 kb promoter/5'UTR region of the genev&r that these factors regulate 
aggrecan expression at other steps in the synthetic pathway. Transcriptional or post-
transcriptional mechanisms are likely to be involved in TGF-P regulation of aggrecan 
synthesis as TGF-p increases aggrecan mRNA expression in primary chondrocytes
(Tuskazaki et al., 1994). Interestingly TGF-p has been found to regulate expression of
the type II collagen gene in chondrocytes at the level of transcription, and requires 
sequences in the first intron of the gene (Bradham et al., 1994). The mode of 
regulation of aggrecan synthesis by IGF-1 has been investigated by Curtis et al. 
(1992). They showed that IGF-1 did not affect mRNA transcription, or post- 
translational processing of aggrecan, and suggest that regulation occurs at the level of 
translation of mRNA coding for aggrecan core protein. In contrast to IGF-1, 
stimulation of aggrecan synthesis by other serum factors occurs at the level of 
transcription (Mcquillan et al., 1986a; Curtis et al., 1992). This is consistent with our 
findings which demonstrated that serum increases aggrecan promoter activity (fig 5-d). 
Although IGF-1 has been identified as a major factor in serum that modulates aggrecan 
synthesis (Mcquillan et al., 1986b), these studies together with our findings suggest 
that other growth factors in serum regulate transcription of the aggrecan gene.
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7.4. Changes in osmolality modulate aggrecan promoter activity
A range of in vitro studies has demonstrated the biosynthetic responses of 
cartilage to mechanical loading. However, the actual signals that the chondrocytes 
respond to are poorly understood. Ionic and osmotic changes have been shown to 
decrease proteoglycan synthesis in chondrocyte cultures and cartilage explants (Urban 
et al., 1993). Our findings demonstrated that osmolality modulates aggrecan synthesis 
at the level of promoter activity, via sequences in the 2.4 kb promoter/5’UTR region of 
the gene. Aggrecan promoter activity was found to progressively decrease in response 
to increasing extracellular osmolality (fig. 5-e A). These findings correspond to the 
decrease in the rate of proteoglycan synthesis in monolayer chondrocytes observed 
between 0.3 Osm and 0.5 Osm as reported by Urban et al.(1993). Regulation of 
promoter activity in response to osmolality was also found to be partly dependent on 
the 5’UTR, as its removal, leaving a 5’ flanking region of -2368 to +25 prevented 
further down-regulation of activity when the media osmolality was greater than 0.3 
Osm (fig. 5-e B). These findings may be important, as the osmolality of articular 
cartilage has been reported to range from 0.35 to 0.48 Osm (Urban and Hall, 1992). 
Therefore the 5’UTR may be important in regulating aggrecan gene expression in 
response to physiological changes in osmolality. Exposure of transfected chondrocytes 
to hypo-osmotic (0.15 Osm) media increased activity of the 2.4 kb promoter 
approximately 50% in the presence of the 5’UTR, and almost 250% when the 5’UTR 
was removed (fig. 5-e A and B). These results suggest that elements upstream of the 
5’UTR regulate aggrecan gene expression in response to hypo-osmotic stimuli. The 
presence of distinct osmotic-responsive regions in the promoter and 5’UTR also 
suggests that separate regulatory mechanisms may be operative for hypo-osmotic and 
hyper-osmotic modulation of aggrecan gene expression in chondrocytes.
The human aggecan 5'UTR was found to contain a single stress response 
element (STRE) at position +237 that may confer responsiveness to hyper-osmotic 
stimuli. STREs modulate gene regulation in Saccharomyces-Cerevisiae in response to 
hyper-osmotic shock (Schuller et al., 1994). Additional sequences are likely to be
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involved in osmotic regulation of aggrecan gene expression as functional studies also 
demonstrated osmotic responsiveness in the 2.4 kb promoter. Osmotic-responsive 
elements sharing a conserved motif have also been identified in the mammalian 
betaine-transporter (Takenaka et al., 1994) and aldose reductase genes (Ferraris et al., 
1996; Reupp et al., 1996). However, the aggrecan promoter does not contain this 
motif, indicating that alternative or novel sequences mediate osmotic regulation of 
aggrecan gene expression.
Exposure of monolayer chondrocytes to osmotic stimuli promoted changes in 
cell size as well as alterations in aggrecan gene expression. Microscopy studies 
demonstrated that hypo- (0.18) and hyper-osmotic (0.58) shock induced time- 
dependent changes in cell diameter (fig. 5-f). Although the cells were approximately 
the same size following long-term (24 hr) exposure, only chondrocytes exposed to 
hypo-osmotic media were able recover to their original size. As aggrecan promoter 
activity was significantly higher under these conditions (fig. 5-e), the transient changes 
in cell size and capacity for recovery are likely to be important factors that control 
aggrecan gene expression following osmotic shock. Osmotic swelling and shrinkage 
have been previously reported for chondrocytes (Urban et al., 1993) and chondrocyte 
volume changes have also been shown to be time-dependent (Urban et al., 1994). 
Osmotic shock also promotes structural changes in chondrocytes which could 
potentially affect aggrecan gene expression. Morphological changes with regard to 
chromatin structure, cytoskeleta! filaments, and the endoplasmic reticulum have been 
observed in pig articular chondrocytes exposed hyper-osmotic (0.48-0.58 Osm) media 
(Borghetti et al., 1994). These observations, together with decreased aggrecan gene 
expression may be part of an adaptation process that enables chondrocytes to function 
in response to the changing physical environment that follows mechanical loading.
In addition to osmolality changes, mechanical loading of cartilage generates 
other environmental changes, including fluid loss, which leads to an increase in 
proteoglycan concentration, and changes in ionic composition, and pH (Urban and 
Hall, 1994). Studies have shown that these factors can also independently regulate the
139
synthetic activity of chondrocytes. Extracellular proteoglycan concentration has been 
found to control proteoglycan synthesis in chondrocytes (Sandy et ah, 1980; 
Heinegard and Paulsson, 1987; Campbell et ah, 1984). Changes in the extracellular 
ion concentration of Na+ and K+ at constant osmolality have also been shown to alter 
proteoglycan and protein synthesis rates (Urban and Hall, 1994). Gray et al. (1988) 
observed that compression mediated down-regulation of proteoglycan synthesis was 
closely associated with increases in interstitial pH. Consistent with our current 
findings, these studies demonstrate that chondrocytes have the ability to respond to 
isolated physical events that follow mechanical loading. Furthermore, cell transfection 
studies have enabled the identification of a specific region of the aggrecan gene i.e. the 
5’UTR, that responds to changes in the osmotic environment.
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7.5. Aggrecan gene expression is regulated by the MEK-1 pathway
A wide range of environmental factors can modulate aggrecan gene expression, 
but the mechanisms by which chondrocytes transduce intracellular signals to the 
nucleus remain poorly understood. The MAPK signalling cascade is a potential 
pathway through which external signals are transduced in chondrocytes. MAPKs are 
known to be activated in response to physical stimuli such as mechanical stress (Tseng 
et al., 1995; Li et al., 1996) hyperosmolality (Matsuda et al., 1995) and ultraviolet 
light (Derijard et al., 1994) and mitogenic signals (Campbell et al., 1994). In our 
current studies we found that aggrecan gene expression in chondrocytes is subject to 
regulation by the MAPK pathway. Inhibition of MAPK kinase (MEK-1) by pre­
treatment of normal and transfected chondrocytes with PD98059 stimulated aggrecan 
mRNA expression and promoter activity approximately 4-fold. MEK-1 is a key 
protein kinase in the MAPK cascade responsible for activation of the extracellular - 
regulated kinases 1 and 2 (ERK-1/2). ERK-1/2 are involved in a number of cell 
processes including proliferation and terminal differentiation in response to 
extracellular signals. ERK-1/2 activities in chondrocytes have been associated with 
proliferation in the presence of mitogenic factors (Legeai-Mallet et al., 1998) and 
mechanical stimuli. The stimulation of aggrecan gene expression in response to 
inhibition of ERK-1/2 activation suggests that the ERK-1/2 pathway negatively 
regulates expression of the aggrecan gene in response to proliferative signals.
In order to determine which external factors may modulate aggrecan gene 
expression through the ERK-1/2 pathway, transfected chondrocytes were treated with 
the MEK-1 inhibitor, and incubated with IL-1 (fig. 6-f) or subjected to mechanical 
stress (fig. 6-g).
EL-1 down-regulated aggrecan promoter activity consistent with the findings 
reported in fig. 5-a. However, treatment with the MEK-1 inhibitor did not prevent IL- 
1-mediated down-regulation of promoter activity, indicating that EL-1 suppression of 
aggrecan synthesis occurs through alternative signalling pathways. Evidence exists to
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suggest that the JNK subgroup of MAPKs (also called stress-activated protein kinases; 
SAPK, or p54 MAPK) are preferentially activated in response to cytokines. In 
chondrocytes, IL-1 activates ERK1/2, JNK, and p38 MAP kinase, but JNK activation 
is more pronounced than ERK1/2 and p38 (Geng et ah, 1996; Scherle et ah, 1997).
Other studies have demonstrated that treatment with IL-1 and TNFa leads to the
activation of the c-jun N-terminal kinase (JNK) subgroup of MAPKs (Sluss et ah, 
1994; Bird et ah, 1994.). JNK signalling in cytokine-stimulated chondrocytes is also 
suggested by the ability of JNK to phosphorylate c-jun, a component of the AP-1 
transcription factor. As discussed previously, AP-1 plays an important role in 
regulating cartilage matrix genes in response to cytokines.
The chondrocyte response to mechanical load was also investigated, by 
subjecting transfected chondrocytes to fluid-flow induced shear stress using a parallel 
plate flow chamber. Fluid-flow induced shear stress was found to decrease aggrecan 
promoter activity via sequences in the 2.4 kb promoter/5'UTR region of the aggrecan 
gene (fig. 5-g) indicating that this region contains elements that regulate gene 
expression in response to mechanical stimuli. Exposure of endothelial cells to fluid 
flow leads to transcriptional regulation of several proteins including monocyte 
chemotactic protein-1 (Shyyetah, 1994), endothelin-1 (Malek et ah, 1993), vascular 
cell adhesion molecule (V-CAM) (Korenaga et al., 1997), EGR-1 (Schwachtgen et ah, 
1998), and Lectinlike ox-LDL receptor -1 (LOX-1) (Murane et ah, 1998). In addition, 
cis-acting regulatory elements that modulate transcriptional activity in response to 
mechanical shear (Shear Stress Response Elements; SSRE) have been characterized in
the platelet derived growth factor- beta (PDGF-P) chain promoter (Resnick et ah,
1993) and the monocyte chemotactic protein-1 (MCP-1) gene (Shyy et ah, 1998). The 
aggrecan promoter was found to contain multiple SSRE motifs 5 -GAGACC-3' 
(Valhmu et ah, 1998a), including three in the 5'UTR, which could potentially 
modulate transcriptional activity in response to shear stress or other mechanical 
stimuli.
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In contrast to IL-1, fluid-flow induced down-regulation of aggrecan promoter 
activity was completely reversed with the MEK-1 inhibitor, PD98059 (fig 6-g). 
Previous studies by coworkers showed an increase in the phosphorylation status of 
ERK-1/2, but not JNK, in untransfected chondrocytes subjected to fluid shear 
(Valhmu et al., 1998b). Thus, fluid-flow induced modulation of aggrecan gene 
expression is mediated primarily through the MEK-1/ERK signalling pathway. 
MAPKs have been found to modulate gene transcription in response to fluid flow in 
endothelial cells. Transcriptional regulation through TPA-responsive elements (which 
are known to bind c-jun and AP-1 transcription factors) is mediated through the Ras- 
JNK pathway (Li et al., 1996), and transcription of the egr-1 gene is mediated through 
the ERK-1/2 pathway (Schwachtgen et al., 1998). These observations suggest that 
common signalling mechanisms are involved in the regulation of endothelial cell and 
chondrocyte gene expression in response to fluid shear. However, these pathways 
may elicit cell-type specific responses. Fluid flow at 35 dynes/cmf increases 
proliferation of bovine articular chondrocytes (Malaviya and Nerem, 1999), but 
completely inhibits proliferation of endothelial cells (Levesque et al., 1990) and 
smooth muscle cells (Sterpetti et al., 1993). It should be noted that levels of fluid flow 
used in the current study are extra-physiological, as fluid flow in cartilage is extremely 
low in vivo. However other physico-chemical phenomena that occur as a result of 
fluid flow are likely to result in chondrocyte deformation, such as electrokinetic forces, 
convective nutrient transport (Garcia et al., 1996) and fluid-induced matrix compaction 
(Lai and Mow, 1980).
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7.6. Specific regions of the aggrecan gene confer responsiveness to 
classical signalling pathways
Regulation by the MEK-1 pathway was dependent on the 5’UTR of the 
aggrecan gene. This was demonstrated by cell transfection studies with aggrecan 
promoter-deletion constructs that showed: 1) promoter deletions to -52 had no effect 
on the PD98059 response; 2) Deletions of the 5’UTR significantly reduced the 
PD98059 response; and 3) the 5’UTR conferred PD98059-responsiveness to a 
heterologous promoter. The region that primarily mediated PD98059 -responsiveness 
was found to be located within +213 to +375 of the 5'UTR. This 162 bp region was 
also found to have a suppressive effect on basal promoter activity, as its removal 
increased promoter activity by more than 2-fold when placed in the context of the 2.4 
kb aggrecan promoter. These findings suggest that the 5'UTR modulates aggrecan 
gene expression by interacting with downstream components of the MEK-1/ERK 
signalling pathway. The ERK-1 and -2 MAPKs are known to phosphorylate a wide 
range of substrates including nuclear proteins and transcription factors such as c-jun, 
Elk-1, c-fos, c-myc, c-myb, Ets-2, EGR-1, NF-IL6, TAL-1, p53, and RNA 
polymerase II (Segar and Krebs, 1995). MEK-1/ERK regulation of aggrecan gene 
expression in chondrocytes may occur through the activation of Ets/p54, EGR-1 or 
TAL-1 transcription factors. This is suggested by the presence of binding sites for 
these proteins in the 162 bp MEK-1 responsive region of the 5’UTR (fig. 7-a).
Signal transduction in response to growth factors also involves other general 
classes of signalling molecules besides MAP kinases, including receptor tyrosine 
kinases and receptor-associated tyrosine kinases. To investigate their role in regulating 
aggrecan gene expression in chondrocytes, transfected cells were treated with specific 
tyrosine kinases. In contrast to the MEK-1 inhibitor study, regulation by tyrosine 
kinases appears to occur through regions within the 2.4 kb promoter, rather than the 
5'UTR (fig. 6-h), indicating that it contains elements that can potentially confer 
regulated expression in response to external signals that activate tyrosine kinases.
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However, with the exception of the EGF-R inhibitor (Tyrphostin AG 1295), the TK 
inhibitors did not affect aggrecan promoter activity when the 5'UTR was present. This 
observation was most clearly demonstrated with the non-specific tyrosine kinase 
inhibitor, Genistein (fig. 6-i). The over-riding effect of the 5'UTR may be due to its 
ability to preferentially bind to transcription factors that are that are common to MEK- 
1/ERK and alternative tyrosine kinase signalling pathways.
The human aggrecan 5’UTR also shares structural similarities with the mouse 
aggrecan 5’UTR which suggest it may have additional regulatory functions. Studies 
by (Liu et al., 1997) demonstrated that the 5'UTR of the mouse aggrecan gene 
contains an enhancer region that binds to scleraxis. Scleraxis is a helix-loop-helix 
transcription factor that is expressed in mesenchymal cells during mouse embryonic 
development (Cserjesi et al., 1995), that can also promote chondrocyte phenotypic 
expression in osteoblasts (Liu et al. 1997). Deletion analysis and functional promoter 
studies identified a 29 bp region, located at +226 in the 5’UTR, that was essential for 
scleraxis enhanced gene expression. The region contained two E-box consensus 
sequences (CANNTG) gapped by three nucleotides, which were critical for scleraxis 
binding and enhanced expression. Interestingly the human aggrecan 5'UTR also 
contains two E-box consensus sequences, gapped by six nucleotides which are 
positioned in a similar location to the mouse gene, at the downstream end of the 
5'UTR (fig 7-a). Furthermore the E-boxes are located in the 162 bp MEK-1 
responsive region. These structural similarities suggest that the function of this region 
of the 5’UTR is not limited to regulating expression in response to MEK-1 signalling, 
and may be involved in regulating developmental expression of aggrecan.
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Figure 7-a. Transcription factor motifs and functional properties of the human 
aggrecan 5’UTR. The 5’UTR contains at least two major regulatory regions: the 
upstream end contains sequences that are essential for basal promoter activity and 
has AP-2/SP-1 binding motifs which may be required for transcription initiation; 
the downstream end (shaded grey) contains elements that regulate promoter 
activity in response to the MEK/ERK-1/2 signalling pathway. The binding sites in 
italics represent transcription factors that are known to be phosphorylated by ERK- 
1/2. The 5’UTR is also involved in regulating aggrecan gene expression in
response to osmolality, IL-1 and TNFa but specific regions have not been
determined.
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7.7. Summary
Our studies demonstrated that the 5'UTR contains at least two major cis-acting 
regions that control transcriptional regulation. One region is essential for high level 
expression of the promoter and is probably involved in transcription initiation, and a 
separate region located at the downstream end of the 5'UTR was found to suppress 
gene expression, possibly in response to proliferative signals. Our studies also 
demonstrated, for the first time, that mechanical and biochemical regulation of 
aggrecan synthesis in chondrocytes occurs at the level of transcription, through 
specific regions of the gene. Although specific regulatory elements were not identified, 
the 5'UTR was found to play an important role in regulating gene expression in 
response to inflammatory cytokines and osmotic stress. Fluid-flow induced 
modulation of aggrecan gene expression is also likely to occur through the 5'UTR as 
this effect was dependent on the MEK-1/ERK signalling pathway. We also 
demonstrated that the promoter was active in both chondrocytes and fibroblasts. 
Therefore additional DNA elements located elsewhere in the gene must interact with 
the promoter to confer chondrocyte-specific expression. Examination of other putative 
regulatory components of the aggrecan gene in combination with the regions identified 
in our studies will provide a greater understanding of the mechanisms that control its 
expression and regulation in articular cartilage.
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